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ABSTRACT
Schmitt, Benjamin Allyn. PhD., Biomedical Sciences Ph.D. Program, Wright State
University, 2021. Alterations in Cardiac Motions of the Failing Heart during Direct
Mechanical Ventricular Actuation.

Objectives: Heart failure (HF) refractory to medical management can be effectively
treated with mechanical support. However, available devices are frequently
associated with complications due to blood contact. Direct cardiac compression
(DCC) devices augment LV systolic pump function by externally compressing the
heart surface. Direct Mechanical Ventricular Actuation (DMVA) is a unique DCC
method providing not only systolic but, importantly, diastolic support. However,
DCC in general remains a relatively poorly understood modality. The purpose of this
study was to examine DMVA’s effect on restoration of physiologic function in the
failing heart.

Methods: Global ischemic HF was induced with 5 mins of ventricular fibrillation
(VF) and circulatory arrest in large mature canines (n=14). Hearts were defibrillated
and DMVA was applied to support HF for 15 mins. VF circulatory arrest was reinduced in subsequent cycles to generate progressively worsening HF. Cycling was
continued for up to 3 hrs or until defibrillation was no longer successful. Animals
were instrumented to record aortic and LV hemodynamics. Intracardiac
iv

echocardiography was used to quantify longitudinal strain and strain rates using
speckle-tracking algorithms. Four areas relevant to function during cardiac assist
were analyzed: (1) pump function, (2) contractile function, (3) intraventricular
dyssynchrony, and (4) device/heart coordination. Results were compared between
baseline, HF, and DMVA. ANOVA with Tukey HSD tests were used to assess
statistical differences (p<0.05).

Results: Aortic indicators of pump function during DVMA were attenuated compared
to baseline, but indicators of pulsatility were substantially increased. Strain and strain
rate waveforms were dramatically augmented by DMVA when applied to the failing
heart. Early diastolic strain rates were substantially augmented during DMVA
compared to baseline. DMVA increased dyssynchrony in a transient manner that was
immediately reversed upon device removal. Increased coordination between the
device and heart motions was strongly associated with higher pressure and pressure
slopes. Poor coordination was characterized by premature intrinsic contraction.

Conclusions: DMVA augmented heart function significantly during severe HF.
Significant boosts to pulsatility and strain-based metrics even during mild HF were
found to be an important feature of DMVA. Some of these findings may be a
characteristic of DCC in general, but diastolic support is a unique feature of DMVA.

v
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I. INTRODUCTION

Brief Background – Direct Cardiac Compression

Heart failure (HF) is a condition affecting approximately five million people in the
United States (although its prevalence is likely higher when considering asymptomatic
cases). Symptomatic HF patients have a predicted 50% mortality rate five years after
diagnosis [46]. Chronic HF is characterized by pathologic anatomical changes and
weakened contractility limiting the heart’s ability to pump blood. Common causes of HF
include ischemic injury via coronary occlusion, hypertension, valvular disease,
myocarditis, arrhythmias, drug overdose, and genetic cardiomyopathies [56,82]. While
the heart is remarkedly adaptive to early cardiac dysfunction, eventually its compensatory
mechanisms are overwhelmed and become pathologic. Increasing mechanical wall stress
creates a feedback loop that progressively weakens the acutely failing heart until function
deteriorates sufficiently to cause cardiogenic shock. Treatment of mild-to-moderate HF
typically consists of lifestyle changes or a myriad of drug regimens. More severe cases
(stages III and IV using New York Heart Association classification) may become
refractory to medical management and require advanced treatments such as cardiac
transplantation and mechanical circulatory support (MCS).
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MCS devices traditionally consist of blood pumps working in parallel to the native heart.
While blood pumps have been in development since the 1950’s, the first use of the axialflow Hemopump in 1988 was a major milestone toward modern designs [29,41]. Prior to
this study, it was assumed bulky pulsatile pumps (utilizing a miniature piston) were
necessary to maintain blood integrity. Concerns were raised whether the impeller used in
axial pumps would create excessive shear forces capable of lysing red blood cells. While
these shear forces were much later shown to disturb clotting factors and platelet function,
the lack of hemolysis in this study paved the way for increased research and adoption of
impeller-driven continuous flow blood pumps. Continuous flow blood pumps required
less power and space than pulsatile pumps and directly facilitated the eventually
movement into fully implantable MCS [63]. The next major breakthrough occurred with
the 2001 REMATCH trials showing dramatically improved outcomes of continuous flow
MCS compared to non-MCS care [97]. INTERMACS, a reporting service that monitors
FDA approved devices, suggests more than 2,500 devices are installed per year with a
total population of approximately 23,000 in the United States [64]. However, the use of
these devices has been greatly constrained by limitations in cost (5-year MCS costs more
than double non-MCS treatments) and patient population (only relatively advanced HF
cases are typically considered) [83]. Additionally, more widespread utilization of these
devices over the past two decades has revealed some not-immediately apparent issues
primarily related to blood contact and continuous flow motors.
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MCS designs have also been adapted for resuscitative roles. Resuscitation survival rates
are surprising low given the emphasis of training in the public sphere. Resuscitation is
mostly limited to treatments defined in the Advanced Cardiac Life Support algorithms
developed by the American Heart Association (AHA), namely the timely application of
close-chest cardiac compressions, defibrillation, and drug regimens (e.g. inotropes and
vasopressors) [85]. Unfortunately, the efficacy of these protocols varies wildly
throughout literature, perhaps due to a lack of uniformity in reporting. Global out-ofhospital rates of return of spontaneous circulation (ROSC) linger around 30% while
survival to discharge remains less than 10% [112]. While in-hospital recovery rates are
substantially better, most instances of cardiac arrest occur in out-of-hospital settings.
Consensus suggests the most important factor for successful resuscitation is minimizing
the time period between the initial cardiac event and treatment [52,110]. However, some
degree of brain damage is likely even after 5 mins of unsupported arrest.

If standard resuscitation protocols fail, MCS devices then become the only means for
restoring critical perfusion in patients. Depending on institutional needs, MCS devices
are available for temporary support (hours to weeks) and long-term (>30 days) or even
permanent support (destination therapy). Temporary support devices are essentially
modified cardiopulmonary bypass (CPB) circuits with a continuous flow impeller using a
peripheral cannulation strategy at easily accessible locations such as the femoral vessels
(Figure 1) [78]. Blood is drawn into a centrifugal impeller and deposited back into
circulation. Alternative MCS designs (such as the Impella device line) insert a catheter
attached to a miniature axial impeller across the aortic valve. Long-term devices, still
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using continuous flow impellers, are based on central cannulation strategies to more
directly and effectively unload the heart (Figure 2) [3]. These devices typically require
more complex and time-consuming installation procedures where an inflow cannula is
placed though the ventricular wall while an outflow cannula is placed through the aorta or
pulmonary trunk. Many long-term devices are fully contained within the thoracic cavity
in an appropriately sized adult chest while pediatric patients require smaller, specialized
pumps.

Manual methods of cardiac compression have been a mainstay medical treatment of
cardiac arrest for decades. In its earliest forms, cardiac compression was achieved by
directly squeezing the heart by hand. Closed-chest cardiopulmonary resuscitation (CCCPR), described and subsequently popularized by Kouwenhoven in 1960, has remained
ubiquitous in emergency routines and largely displaced open-chest cardiac massage for
maintaining perfusion in non-traumatic cardiac arrest before defibrillation [65]. Openchest cardiopulmonary resuscitation (OC-CPR) is now only recommended for traumatic
cardiac arrest involving chest injury i.e. situations that would already require
thoracotomies needed to directly access the heart. While closed-chest compressions avoid
the invasiveness of resuscitative thoracotomies, numerous studies have suggested
coronary and cerebral circulation are superior during OC-CPR compared to CC-CPR
[15,38]. This difference likely stems from the indirect nature of CC-CPR support, via its
manipulation of intrathoracic pressure, rather than the direct manipulation of the heart
seen in OC-CPR [27]. Regardless, maintaining OC-CPR at physiologic rates is a
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physically taxing and potentially uneven process that would directly benefit from
automation.

Direct cardiac compression (DCC) is a form of external cardiac support that can be
considered an automated form of OC-CPR. These devices are engaged around the
epicardium and actuated with an external pneumatic drive system [51,84]. The concept
has received considerable speculation over the years, with patents issued as early as 1936
[81]. The Anstadt Cup, with its earliest form introduced in 1965, was the first device to
receive serious attention and testing. Alternative devices have branched out from this
early concept with a variety of different mechanisms and features (Table 1). While each
device has unique features, devices either consist of: (1) a fluid (usually air but some
devices use saline) used to inflate a self-contained sac on the epicardium to pump the
existing heart structure or (2) a sheathe placed over the epicardium that relies on tension
to squeeze the heart.

Closer examination of DCC history reveals two phases driven by concurrent
developments in blood pump technology. Older devices (created 1965-2000), such as the
Anstadt Cup [7,10], Abiobooster [60], Cardiosupport System [111], HeartPatch [55], and
Pedibooster [60-61], were developed primarily to maximize hemodynamics and were
considered for a variety of support roles (resuscitation, bridge-to-transplant, bridge-torecovery, destination therapy). Despite promising developments in these systems, the
advent of fully implantable blood pumps largely relegated experimental DCC to
applications during resuscitation where the lack of full implantability was less limiting.
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The focus of newer devices (created 2000-present), such as the EpicHeart, soft robot,
foam actuator, and muscle-powered experimental devices, has been an effort to reclaim a
long-term support role by attempting to create more physiologic heart motions via
external support (Figure 3). EpicHeart features an inflatable bladder conformed to the
shape of the heart whose main feature is ease of implantability facilitated by a collapsible
Nitinol skeleton [53]. The soft robotic sleeve uses a pneumatic muscle network to mimic
physiologic cardiac fiber orientation and contraction [54]. The foam actuator design uses
special foam embedded in a cup-like structure to better mimic physiologic strain [74].
More recently, a system utilizing a muscle-powered piston fully contained within the
chest cavity to pump a cup-like structure over the heart has been developed [51,105].

Regardless of claims about the importance of greater physiologic fidelity in more recent
DCC research, the main attraction of DCC remains the near-total elimination of blood
contact. Blood pumps require invasive cannulation strategies, expose blood to nonbiological surfaces (necessitating anticoagulants), generate abnormal forces on the blood
due to impellers, and increase the risk of infection [89,92]. Additionally, continuous flow
devices lack improvements in perfusion and endothelial signaling that accompany
physiologic pulsatile flow [20,22,26]. While these issues are unlikely to change the
practical utility of blood pumps in the short-term and are being partially mitigated by new
device features, avoiding blood contact entirely gives DCC considerable appeal.

There are reasons to suspect long-term use of DCC in general may be more beneficial
than blood pumps to myocardial recovery. Cardiac myocytes are incredibly reliant on
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mechanical stimulation to retain contractility [76,101]. It is well known excised myocytes
rapidly lose the ability to contract without imposed mechanical stimuli [2,77]. Unloading
the heart using a blood pump promotes atrophic reverse remodeling. Atrophic reverse
remodeling is beneficial to the heart to correct pathologic remodeling (i.e. hypertrophy)
during HF. However, long-term unloading parallel to the native heart structure has shown
some evidence of a detrimental impact on intrinsic contractile function [32,91]. External
support has the benefit of directly actuating the myocardium while concurrently
supporting the heart. It has been speculated DCC could mitigate long-term atrophy by
simultaneously conditioning cells with imposed strain while reducing the heart’s
workload. Cellular conditioning from DCC may have important implications in
promoting myocardial recovery, although the cellular pathways governing this effect
have not been well characterized.

Given these benefits and research efforts, it may seem surprising that no DCC devices
have ever progressed beyond the level of limited clinical testing. The main obstacles for
DCC adoption have historically been the lack of full implantability, the already
significant investment in blood pump technology (relative to the projected patient
population), and questions about durability. The use of blood pumps soared primarily due
to technological innovations allowing size reductions and greater implantability without
major apparent drawbacks in health outcomes. Every DCC model to date has used either
pneumatic or, to a lesser extent, liquid-powered pumps to actuate respective devices
[51,81]. It is unlikely either modality will facilitate easy implantability on the level of
continuous flow blood pumps without significant reductions in support given limited
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space in the thoracic cavity and the level of miniaturization needed for pumps. For this
reason, realizing full implantability has become the primary goal for all experimental
DCC devices.

8

Figure 1 - Common Temporary LV Acute Mechanical Assist Devices: Devices are
grouped by mode of action. Intra-aortic balloon pump (IABP) reduces afterload and
improves coronary perfusion. The Impella CP and Percutaneous Heart Pump (PHP) are
axial flow pumps placed directly across the aortic valve. TandemHeart and veno-arterial
extracorporeal membrane oxygenation (VA-ECMO) are extracorporeal devices that
pump blood through peripheral cannulation sites. (Figure adapted from [35])
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Figure 2 - Common Long-Term Mechanical Assist DevicesDevices are grouped by mode
of action: (A) Pulsatile pump using a small piston in an artificial chamber, (B) Axial
continuous flow pump with impeller in line with flow, (C) Centrifugal continuous flow
pump with impeller perpendicular to flow, (D) Magnetically-levitated centrifugal
continuous flow pump to reduce friction. (Figure adapted from [35])
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Table 1 – List of Major DCC Devices throughout History
Major DCC Devices
Anstadt Cup (DMVA)
Abiobooster
Cardiosupport System
Heart Patch
Artificial Myocardium
Pedibooster
EpicHeart
Soft Robot
Foam Actuator
Muscle-Powered

Features
Semielliptical cup placed over the epicardium
Cuff-like structure with individual compression cells
Inflatable cuff contained within a cup-like structure
Patches placed on the ventricles
Patches taking the shape of the heart surface
External heart patch using a balloon for pediatric patients
Minimally-invasive (collapsible) padded cup-like structure
Pneumatic muscles mimicking cardiac fiber orientation
Pneumatically-inflated foam in a cup-like structure
Shoulder muscle used to move piston using energy converter

11

Figure 3 – Other DCC Devices Currently in Development: (A) EpicHeart [53], (B) Soft
Robot [54], (C) Foam Actuator [74], (D) Muscle-Powered [51,105].

12

Direct Mechanical Ventricular Actuation

Direct Mechanical Ventricle Actuation (DMVA, Figure 4) is the nomenclature used to
describe fundamental attributes of the Anstadt Cup [10,84,88]. DMVA is uniquely
efficacious for providing resuscitative support by virtue of its short installation times (< 5
mins), elimination of the need for anticoagulants, ability to generate biventricular
pulsatile flow, and diastolic assist. The device consists of a polymer cup placed over the
ventricular epicardium with a hard-outer shell enclosing a flexible polymer diaphragm
(Figure 5). The space between the outer shell and inner diaphragm is pneumatically
isolated save for its connection to a pulsatile drive system. Ventricular actuation is
achieved by cyclic introduction and removal of air in this space which acts to expand and
retract the flexible diaphragm, respectively. The expanding diaphragm takes on a concave
cross-section that variably compresses the ventricular surface from the heart apex to the
base just under the AV groove (actuation zone). These forces can be directly translated to
the heart assuming a tight coupling between the inner diaphragm and heart surface.

Proper fixation is achieved by a continuous low-magnitude vacuum delivered via the
apical port. This vacuum also serves to prevent expulsion of the heart due to basaldirected forces during systolic compression. While a variety of fixation methods are
available for DCC (mechanical restraint anchored to the basal heart, chemical attachment,
and tissue integration [54]), apical pneumatic suction permits easier device placement
while allowing for quick removal and avoids damage to cardiac structures. DCC in
general provides active systolic assist but relies on passive relaxation to refill during
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diastole. DMVA’s most compelling feature has been its active diastolic assist facilitated
by rapid air removal from bladder. DMVA’s unique diastolic suction effect may dilate
coronary vessels and facilitate improved coronary perfusion during DMVA support [10].
Given the early role of diastolic dysfunction in cardiac pathologies and the key role of
diastole in coronary circulation, augmented diastolic support has important therapeutic
implications.

Previous animal studies have demonstrated DMVA’s capacity to generate near-normal
hemodynamics following total circulatory arrest in the fibrillating or non-beating heart
[8-14,23,49]. Laboratory and clinical investigations have demonstrated DMVA’s
superiority in cardiac and cerebral resuscitation when compared to closed-chest
compression [23], open-chest cardiac massage [6,49], and CPB [11-14]. Compared to
CPB, resuscitative DMVA showed significantly improved neurologic recovery following
experimental cardiac arrest [11,13]. This was accompanied by improved neuronal
preservation within the hippocampus of animals supported by DMVA compared to CPB
one week after resuscitation [10]. Importantly, DMVA appeared to provide support in an
atraumatic manner as elevations in myocardial stress and proapoptotic biomarkers were
attenuated during DMVA support in an acute HF model [7]. Clinical experience has
demonstrated support of the failing heart for up to three months without evidence of
significant myocardial trauma [71-72]. DMVA produced myocardial strain and strain rate
magnitudes comparable to the physiologic unsupported beating heart in both small
animal studies [7] and preliminary large animal studies.
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Figure 4 – DMVA Schematic: DMVA provides(left) diastolic retraction and (right)
systolic augmentation. Actuation occurs via expansion and retraction of a thin inner
membrane at the heart surface using a pulsatile pneumatic drive system. An apical
vacuum prevents expulsion of the heart during actuation and facilitates a tight seal
between the expandable membrane and heart.
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Figure 5 - DMVA Pictures: (Left) Photo of the silicone rubber DMVA device without a
heart. (Right) Photo of the DMVA device on the heart during systolic compression.
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Importance of Pulsatility

Pressure pulses play a significant role in endothelial vascular signaling and perfusion.
Non-pulsatile flow (NPF) systems reduce complexity, size, and energy requirements
relative to pulsatile flow (PF) devices. Whether NPF during MCS negatively impacts
outcomes remains controversial. Studies have identified differences between NPF vs PF
with respect to capillary, venous and lymphatic flow, and end-organ function (Table 2)
[20,26,59,100]. However, differences in effectiveness between NPF vs PF devices in
clinical practice have been inconclusive. Clinical results lack robust randomized trials or
relevant comparative data given the relatively limited patient numbers for such devices.
Recognizing this cause for concern, many NPF systems are imparting a measure of
pulsatility by cycling impeller rates (albeit at the cost of higher demand on the power
source and more device fatigue). Regardless, existing (and largely discontinued) PF
blood pumps may not even generate truly physiologic flow characteristic given the use of
an artificial chamber instead of the native heart structure.

Early return of spontaneous circulation (ROSC) is the single most critical factor for
improved neurologic outcomes [52,110]. ROSC inherently restores physiologic PF,
suggesting PF during MCS may be vital for effective reperfusion following cardiac
arrest. Reestablishing normal cerebral and vital end-organ function is the primary goal
following unexpected cardiac arrest and/or cardiovascular collapse. Neurologic injury
and end-organ dysfunction remain significant causes of morbidity and mortality in
patients receiving MCS [66]. Prior investigations provided compelling evidence DMVA
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improved cerebral resuscitation outcomes and neurological recovery compared to CPB in
animal models [12-14]. These findings were considered primarily due to timely return of
physiologically normal PF via actuation of the existing heart structure. While these
claims are probable given DMVA’s mode of action, pulsatility generated during support
has not been quantified to verify this phenomenon.
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Table 2 - Summary of Complications Associated with Vascular Non-Pulsatile Support:
While continuous flow devices offer greater implantability, non-pulsatility has been
associated with greater incidence of adverse health outcomes [20,26,59,100].

19

Echocardiography Strain Imaging

Echocardiography (ECHO) has been a useful tool for cardiac visualization and
characterization of heart morphology and function [7]. ECHO is primarily acquired using
transthoracic, transesophageal (TEE), and intracardiac (ICE) techniques. While TEE
remains the most common clinical modality, it has not been ideal for testing DMVA
given the ultrasound beam must pass through the air-filled device from most relevant
positions in the esophagus. The air interface prematurely reflects most of the ultrasound
signal and obscures cardiac imaging. While some views are possible with probes
positioned high in the esophagus, ICE was found to produce clearer imaging by virtue of
being closer (vena cava or right atrium) to the relevant heart structures (Figure 6) [34].
Example 2D images acquired using a variety of ICE probe rotations can be observed in
Figure 7. Each plane represents a distinct slice of the left ventricle (LV). Convention
dictates the LV can be divided into 17 segments using a combination of standard views
(four-chamber, two-chamber, and long-axis), although in practice not all these regions are
necessarily characterized in most studies (Figure 8) [98]. While ICE is ideal for
evaluating DMVA, comparative studies measuring strain using this technique are limited.
Most applications of ICE are strictly for visualization purposes during cardiac surgeries.

Strain and strain rate metrics have emerged as powerful quantitative estimates of
myocardial function and contractility [4,44,86,90,104,108]. Strain is the deformation of
an object compared to its original length while strain rate is the rate at which that relative
deformation occurs (Figure 9) [70]. Strain rate in particular has shown promise as a
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somewhat load-independent measure of myocardial contractility [90,108]. LV strain and
strain rate can be measured along three axes: longitudinal, radial, and circumferential
(Figure 9). Longitudinal strain measurements are derived from long-axis views of the
heart while radial and circumferential strain measurements are derived from short-axis
views. Measurements of the longitudinal plane are ideal for testing DMVA as slices pass
through more tissue and allow the non-uniform dimension of DMVA to be characterized
(important given the radial symmetry of the device). In addition to the difficulty of
acquiring true short-axis planes during DMVA, longitudinal strains and strain rates are
more sensitive estimates of systolic function than pump function metrics and more
readily detect subclinical cardiac pathologies [99].

To characterize longitudinal strains and strain rates the cardiac wall boundary must be
successfully identified for each frame of an ECHO clip. The two primary methods of
tracking cardiac movements are tissue Doppler imaging and speckle tracking [90].
Doppler measures instantaneous tissue velocity gradients in small myocardial segments
that can be converted to strain. However, Doppler is highly angle-dependent and could be
problematic during DMVA support (particularly in the open chest) due to DMVA motion
artifacts. Speckle tracking uses randomly distributed acoustic markers (speckles) to
uniquely characterize a region on interest (ROI) within an ultrasound image [102].
Speckles (once thought to be merely extraneous noise) are caused by reflections from
microscopic tissue boundaries, thereby giving every ROI a characteristic speckle pattern.
Each ROI can be followed over several consecutive frames (necessitating a sufficiently
high frame rate) before out-of-plane tissue motions change the speckle pattern and force
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reevaluation. After the user traces relevant boundaries in a reference frame, these points
are tracked throughout the entire ECHO clip. Frame-to-frame changes can be tracked
using sum of absolute difference algorithms [102]. In addition to its relatively angleindependent nature, speckle tracking only needs a single cardiac cycle and can be
performed offline using 2D images. Speckle tracking strain and strain rate have shown
good agreement with sonomicrometry, the gold standard, when measured under varying
conditions [90].
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Figure 6 - Comparison of Transesophageal Echocardiography (TEE) and Intracardiac
Echocardiography (ICE) Images. Both images were captured in the same canine subject
and represent equivalent 4-chamber views.
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Figure 7 – Example LV ECHO Views Captured with ICE. Achievable views were: 4chamber long-axis (probe in RA), 4-chamber long-axis (probe in RV), 2-chamber longaxis, and an imperfect short-axis view.
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Figure 8 – Representation of the 17 standard regions from TEE analysis. (Figure adapted
from [98])
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Figure 9 – Definition of Strain Used in this StudyLongitudinal axis strain has been the
most accessible for DMVA given the difficulty of achieving pure short-axis views
through the air-filled device.
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Dyssynchrony during DCC

Concerns have been raised regarding the extent of aberrant ventricular wall deformation
due to DCC [30]. While different devices may impose their own distinct actuation
profiles on the heart, external compression as a mechanism is likely to impose some
unusual timing compared to inherent muscle contraction. There are three types of cardiac
dyssynchrony: intraventricular (timing of contraction along a ventricular wall),
interventricular (timing of contraction between the two ventricles), and electrical (timing
of mechanical contractions with electrical stimuli) [19]. Dyssynchrony measures are
typically used to diagnose cardiac pathologies where large timing differences are
correlated with wasted energy and compromised electrical function during HF [103]. In
clinical practice, these pathologies can be treated using cardiac resynchronization therapy
(CRT) [68]. CRT uses electrodes implanted in the ventricles to reestablish more normal
ventricular electrophysiology and contraction. These same measures used by
cardiologists for CRT can also be applied in experimental settings to assess the effect of
DCC on electrophysiologic aberrancies during support of the failing heart.

Common methods of assessing intraventricular dyssynchrony are opposing wall delay
(OWD) and dyssynchrony index (DI) [25,42,47-48,57,107]. Both methods rely on ECHO
interrogation of the heart. OWD is typically defined as the time delay between peak
contraction of matching regions between the septum and free wall. While formulas can
vary, the general idea of DI is to measure the standard deviation of the time differences
between a reference point, typically the QRS peak, and peak systolic compression.
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Mechanical Pacing

Implanted electrical pacemakers are an effective and widely utilized means of pacing to
correct arrhythmias, particularly bradycardia and heart block. Electrical activation of
calcium-dependent ion channels triggers mechanical contraction. However, this
excitation-contraction coupling pathway works in reverse as well. Mechanical
perturbations can activate cation-non-selective stretch activated channels at the site of
myocardial depression, thereby triggering electrical depolarization [39-40,93,95]. Optical
mapping of mechanical stimulation in isolated rat and rabbit hearts demonstrated
electrical signals are generated at the site of mechanical indentation and proceed into
adjacent tissue in an identical manner to those generated via electrical pacing [94].
Validation of this phenomenon has primarily been conducted in-vitro with cell-stretching
rigs or ex-vivo using indenters (Figure 10).

Ventricular capture refers to the ability of external stimuli to influence cardiac electrical
activity [43]. This electrical stimulus is naturally generated by pacemaker cells in the
sinoatrial node to capture other regions of the heart with slower repolarization. With a
cardiac pacemaker, the goal is to electrically capture the ventricles by imposing a faster
rate that preempts intrinsic contraction. Loss of capture occurs when the pacemaker loses
control of cardiac timing. The same ideas can be applied to electrical signals generated by
mechanical stimuli [36]. The sustainability of indenter-based mechanical pacing in an
isolated heart model has been questioned due to conditioning effects and spontaneous
loss of capture with repeated use [94]. However, it is unknown to what extent mechanical
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stimuli from uniform cardiac compression will promote mechanical pacing or ventricular
capture. DMVA in its current form does not use electrical pacing and relies purely on
mechanical pacing, making it an ideal testbed for studying the mechanical pacing
phenomenon in vivo.

Most clinical reports of the mechanical pacing phenomenon focus on either
mechanically-induced pathologies or archaic pacing therapies. Commotio Cordis, the
induction of ventricular fibrillation due to a precordial impact with no obvious damage to
the heart structure, is the earliest recorded condition related to the ability of mechanical
stimuli to induce arrythmias in a healthy heart [37]. Precordial thumping, the reverse of
Commotio Cordis, uses a similar impact to defibrillate the heart in certain emergency
settings [75]. A milder form of thumping is used in percussion pacing. Percussion pacing
involves delivering a blow (starting out 20-30 cm above the body) to the sternum near the
right atrium [33,45]. Both precordial thumping and percussion pacing have been
relegated to emergency placeholders until electrical pacing can be administered due to
worries about worsening arrythmias and low efficacy. Zoll, famous for his work with
electrical pacing, constructed a system that trans-thoracically defibrillated the heart using
mechanical stimuli [95]. Following the same pathways, the topic of CPR-induced
arrythmias has generated considerable discussion. While CPR is primarily used to pump
the heart without consideration for pacing, mechanical stimuli during CPR appear to
disrupt electrical activity [21]. The zone of vulnerability occurs just before the T-wave
with dispersed polarization if the fibrillatory threshold is reached [95]. The lack of impact
(like thumping or percussion pacing) during DCC due to the tight interface between the
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heart and devices under normal operation likely accounts for why DCC devices have not
been associated with induced fibrillation.

Device Tuning

It is known that DCC devices in general are constrained in their ability to augment flow
in healthier hearts. At certain underlying levels of pump function (~70-80%), DCC will
begin to have a derogatory effect [17-18]. Tuning the DMVA cup involves selecting
both the correct cup operation parameters and size based on subject anatomy and
physiology [87]. If the device is too small the heart will either tend to be ejected or the
device will slide down the heart’s surface (thereby limiting the effective pumping area).
If the device is too large the seal between the it and heart will be ineffective, potentially
to the point where cavitation is observed. Cup sizes are currently selected based on
visual confirmation, particularly at the level of the AV groove. Similarly, adequate
driving pressures must be used to ensure proper support. Insufficient pressure will cause
inadequate compression while excessive pressure may limit diastolic filling. Abrupt
change in pressure could also result in the heart detaching from the inner membrane.
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Figure 10 – Ex Vivo Evaluation of Mechanical Pacing: Examples of ventricular capture
and loss of capture in an isolated perfused rabbit heart using a localized mechanical
indenter [94].
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II. HYPOTHESIS AND SPECIFIC AIMS

HYPOTHESIS

The primary focus of this dissertation was determining whether delivery of mechanical
forces via DMVA during heart failure restores near-physiologic cardiac function. Cardiac
function was defined using four categories (corresponding to the specific aims) for the
purpose of this investigation: (1) pump function, (2) myocardial function, (3)
intraventricular dyssynchrony, and (4) device/heart coupling.

SPECIFIC AIMS

Aim 1: Determine if LV pump function during DMVA is improved to approximate
baseline physiology. Pump function is the mechanical ability of the heart to eject blood
from the ventricle during systole and refill during diastole. DCC devices have been
almost exclusively evaluated in terms of their ability to augment pump function. A
common characteristic of DCC pump function is a ceiling to beneficial support in more
robust hearts. Limitations in arterial-ventricular coupling and elastance mismatches are
likely responsible for this phenomenon. DMVA in particular has been shown to result in
physiologic coronary flows and cerebral perfusion relative to CPB. It is thought pulsatile
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actuation using the native heart structure was the primary reason for greater perfusion
compared to continuous flow alternatives. DMVA support during HF was
hypothesized to improve pulsatility to approximate baseline values despite DCC’s
propensity for decreased maximal hemodynamics.

Aim 2: Determine if LV contractile function during DMVA is improved to
approximate baseline physiology. A major limitation of pump function metrics is a lack
of information about underlying tissue mechanics. The ability to pump blood is a measure
of cardiac workload and is only indirectly related to the contractile properties of the heart
muscle itself. Peak strain and strain rate magnitudes have served as common surrogate
measures of cardiac stretch and compression, respectively. Composite strain and strain
rate waveforms were calculated in this study to examine trends obscured by peak
magnitude metrics. DMVA support during HF was hypothesized to improve strain
and strain rate waveforms to approximately baseline values.

Aim 3: Identify if LV cardiac timing is altered during DMVA compared to native
heart function. DCC has a unique capacity (compared to other methods of cardiac assist)
to alter the timing of perceived ventricular compression by imposing forces on the heart
surface. However, it remains unknown if external actuation meaningfully alters left
ventricular wall timing. DMVA support during HF was hypothesized to maintain
native cardiac timing during support of the failing heart.
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Aim 4: Determine if DMVA is capable of exerting a coordinating effect on the heart
without electrical pacing. Cardiac function during DCC is a combination of impaired
native wall function and imposed external forces. The interaction between these two
mechanisms can increase hemodynamic variability and negatively impact overall cardiac
function. Mechanical signals alone have demonstrated the ability to mechanically pace
cardiac tissue in vitro and isolated heart preparations ex vivo. While untested in vivo, this
mechanical pacing phenomenon may reduce variation between DCC’s mechanical
stimulus and the overall hemodynamic response. DMVA support during HF was
hypothesized to have a significantly weaker coordination effect than that exhibited
during DMVA support during ventricular fibrillation (VF). More robust
mechanical signals are expected to enhance coordination between the device and the
heart.

34

III. MATERIALS AND METHODS
The Wright State University Lab Animal Care and Use Committee approved the
experimental protocol, and all animals were treated in compliance with the Guide for the
Care and Use of Laboratory Animals of the National Academy of Sciences published by
the National Institutes of Health, revised 2011 [79].

Resuscitation Model
Mature mixed breed large canine (63.7 ± 13.4 lbs, n=14) were evaluated with a
resuscitation model using repeated periods of cardiac arrest to generate variable HF
(Figure 11). Animals were anesthetized (1-2% isoflurane), underwent median sternotomy
and pericardiotomy, and were instrumented for hemodynamic monitoring. VF was
induced via application of a 9 V DC to the epicardial surface. Normothermic circulatory
arrest was subsequently maintained for 5 mins. DMVA was then engaged over the
exposed epicardium for a 15-minute support period. At the end of this timespan, DMVA
was removed for a series of defibrillation attempts. VF refractory to three successive
countershocks was treated with an additional 15 mins of DMVA support, after which
defibrillation was re-attempted. With successful defibrillation and return of spontaneous
circulation, animals were monitored for 5 mins before applying DMVA to the beating
heart for 15-mins. Other than administration of standard doses of lidocaine, no other
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cardiovascular agents (such as vasopressors or inotropes) were administered during the
experimental period. Intravenous fluids were added to maintain central venous pressures
in the normal physiologic range. This cycle was repeated for up to 3 hours (Table 3)
dependent on animal survivability.
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Figure 11 - Fibrillation-Induced Resuscitation ModelRepeated cycles of
fibrillation/defibrillation were used to generate varying levels of HF for DMVA
evaluation. Experiments were continued for up to three hours after the initial VF event
(dependent on animal survivability).
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Table 3 – Experimental Duration Per Subject: The average experimental time period for
accepted animals, defined as the time between the initial induction of VF and beginning
of the final recovery period before euthanization, was somewhat more than two hours.
However, no experiments exceeded three hours.

Canine
1
2
3
4
5
6
7
8
9
Average

Timeframe afer
Initial VF (min)
117.6
116.5
142.4
167.8
104.7
124.4
159.0
122.0
93.4
127.5
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Instrumentation

A computer data acquisition system (LifeWindow 6000 system; Digicare, Boynton
Beach, FL) was used to record surface electrocardiogram, hemodynamics, pulse
oximetry, end-tidal carbon dioxide, and rectal temperatures for monitoring subjects in
accordance with established protocols. All reported data was derived from measurements
of: (1) aortic flow, (2) aortic pressure, (3) LV pressure, (4) DMVA pneumatic pressure,
and (5) strain and strains rates from ECHO captures (Figure 12).

A TS420 perivascular ultrasonic flowmeter (Transonic Systems, Ithaca, NY) measured
blood flow via a 14-16 mm Confidence probe wrapped around the ascending aorta. Two
P23XL transducers (Spectramed Inc., Westlake Village, CA) were used to measure blood
pressures (LV and aortic). A butterfly catheter was positioned in the LV via the right
carotid artery while another catheter was positioned in the ascending aorta via the left
carotid artery. A Microswitch 143PC05D (Honeywell International, Inc, Morris Plains,
NJ) transducer measured DMVA’s pneumatic pressure from a side port in the drive line.
Pressures and flows were periodically collected throughout experiments in 10 s capture
periods at 800 Hz using LabVIEW data acquisition software (National Instruments,
Austin, TX). A 5-10 MHz ACUSON AcuNav 10F intravascular catheter was positioned
in the right atrium via the right jugular vein to generate 2D ICE images. Images were
captured and processed using the Acuson Sequoia C512 ultrasound system (Siemens
Medical Solutions, Mountain View, CA).
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Figure 12 – Diagram of Relevant Canine Instrumentation: Animals were instrumented to
collect 2D ICE images, aortic flows and pressures, LV pressures, and DMVA pneumatic
pressures.
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DMVA Drive Settings

DMVA pneumatic pressures were generated in a reproducible fashion (Figure 13).
Waveforms were directly characterized by maximum pressure, minimum pressure, and
cycle length. These settings were used to calculate secondary parameters such as rate of
pressure change (dP/dt), pressure integral, and device systolic duration. Maximum
systolic pneumatic pressures were adjusted to cover a wide range (60-200 mm Hg peak
pressure) of device capabilities. Minimum diastolic pneumatic pressures were set to
threshold values that enabled full retraction of the inner membrane to the outer shell. A
localized peak detector was used to quantify positive and negative pressure extrema for
every actuation cycle. Pressure cycles were defined by all data between adjacent negative
DMVA pressure peaks. Actuation frequencies were adjusted to simulate physiologic
heart rates (110-130 bpm) characteristic of the large canine model used in this study.

A low intensity (<100 mm Hg) apical vacuum was used to maintain appropriate heart
retention in the device during actuation and pneumatic coupling. Canine hearts were
fitted with appropriately sized DMVA devices ranging between 80-90 mm short-axis
diameters based on ECHO estimates of heart diameter at the AV groove. Running
assessments of device fit relied primarily on visual inspection of cardiac actuation during
DMVA support. The open chest protocol allowed for rapid exchange of devices to
achieve best fit throughout the experiment. Hearts experiencing dilation as experiments
progressed required substitution with larger devices.
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Figure 13 – Example DMVA Pneumatic Pressure Waveforms: Pneumatic device
waveforms were characterized in terms of maximum and minimum pressures, four
average pressure change rates (dP/dt), cycle length, and device systolic duration.
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Data Management

At least one successful defibrillation attempt was necessary for inclusion of an animal in
the final analysis. Nine subjects had adequate survivability and data quality to meet the
requirements for further analysis. However, only six of these subjects had acceptable LV
pressure readings. Data was divided into five experimental states: (1) baseline, (2)
unsupported VF, (3) unsupported HF (varying levels), (4) DMVA support during VF, and
(5) DMVA support during HF.

Hemodynamic (aortic flow, aortic pressure, LV pressure) and device pressure data were
used to compute results seen in Aims I and IV. Individual 10 s captures from this data
pool containing two experimental states (transition capture) were eliminated for better
standardization. At least 12 cycles were necessary for inclusion of hemodynamic
captures. Total acceptable captures for each state are displayed in Table 4. All signals
were smoothed using a 10-point moving average filter. All mathematical analysis of raw
data was carried out in MATLAB (MathWorks, Natick, MA). Captures were further
stratified (Table 5) into categories based on mean aortic flows for each state relative to
baseline: 25-50% (severely impaired), 50-75% (moderately impaired), 75+% (near
physiologic). As noted in subsequent results, DMVA data was also grouped according to
the extent of underlying HF relative to baseline (using the same above categories).
Underlying function during DMVA used captures either just before device placement or
just after device removal so they could be associated with a nearby (within 3 mins) HF
capture.
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ECHO data was used to compute results seen in Aims II and III. ECHO captures during
DMVA were stratified into categories based on underlying (i.e. non-support) global strain
relative to baseline: 0-33% 33-66%, 66-100%, and 100+%. Underlying function during
DMVA used captures either just before device placement or just after device removal so
support captures could be associated with a nearby (within 3 mins) HF capture. Instances
of hyperdynamic underlying function (100+% category) during the HF period, while not
fitting the definition of HF, provided information about cardiac response to the insult and
how this affected DMVA support.
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Table 4–Data Capture Distribution: Number of 10 s hemodynamic data captures
represented in each experimental state for aortic and LV hemodynamics.

45

Table 5 – Distribution of Data Captures by Flow Category: Number of 10 s captures for
baseline, HF, and DMVA organized by flow category relative to baseline. Captures were
substantially represented in every flow category.
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Pump Function

LV pump function, the ability to pump blood into the systemic circulation, was
characterized by parameters derived from aortic flows, aortic pressures, and LV pressures
for each cycle within accepted data captures. Aortic flows were characterized by mean
and maximum values. The integral of aortic flow for each cycle was used to compute LV
stroke volume (the volume of blood pumped into the aorta during one cardiac cycle). LV
pressure was characterized by the signal’s maximum pressure. Aortic pressure was
characterized by systolic (maximum pressure), mean aortic pressure (MAP), diastolic
(minimum pressure), average +dP/dt (upslope pressure), and average -dP/dt (downslope
pressure). Aortic power integral, a general measure of cardiac workload (and an estimate
of stroke work), was calculated as the integral of the product of aortic flow and MAP for
one cycle. Measures within the same 10 s capture were averaged together to represent
that capture.
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Pulsatility Parameters

Aortic pressures and flow waveforms were used to calculate pulse pressure (PP), energy
equivalent pressure (EEP), surplus hemodynamic energy (SHE), pulsatility index (PI),
and pulse power index (PPI), as defined in Table 6 [24,62,100,106,109]. Flow and
pressure were aligned for each capture using cross-correlation to correct for minor phase
shifts and standardize results. PP was calculated as the range of aortic pressure for each
cycle. EEP, a measure of total energy, was calculated as the integral of the product of
aortic pressure and flow divided by the integral of aortic flow. Therefore, EEP can be
interpreted as work needed to pump a volume of blood. SHE, the pulsatile component of
EEP, was calculated by subtracting MAP (the continuous component) from EEP and
multiplying with an energy conversion factor [58,100]. PI was calculated by comparing
the sum of squared amplitudes of the first five aortic flow harmonics (pulsatile
component) to the squared amplitude of 0 Hz aortic flow signal (continuous component)
[62]. Harmonic amplitudes were measured at multiples of the fundamental frequency in
the Fourier transforms of aortic flow (Figure 14). PPI is a modification of PI derived by
multiplying harmonic amplitudes by angular frequency before being squared and
summed in order to amplify high frequency values.
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Table 6 - Definitions of Pulsatility Metrics Derived from Aortic Hemodynamics
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Figure 14 – Example Aortic Flow and Frequency Spectrum: The aortic flow waveform
with its corresponding spectral breakdown showing 0 Hz (A0) and example harmonic
amplitudes (A1-10).
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ECHO Analysis

Given the historical irregularity of ICE usage for strain rate analysis, the first step of any
systolic analysis using this technique is to define relevant ECHO planes (Figure 15).
Standard views in TEE ultrasound were used as a basis for defining ICE regions. A 4chamber ICE view was considered optimal given it was the default view from the probe
location, had the most representation in captures, and allowed for longitudinal
strain/strain rate measurements. While long-axis (2-chamber) and short-axis ICE
equivalents were captured, these were not included within the scope of this study. The 4chamber view was used for all subsequent analyses to improve consistency. Grossly
foreshortened views, showing a plane that did not transect the center LV apex, were
excluded.

ECHO clips were selected based on proper delineation of the LV cardiac wall throughout
the entire cycle, visualization of the mitral and aortic valves, and necessarily included at
least one full cardiac cycle. While meeting these criteria, effort was made to sample
evenly throughout the experimental timeframe. Captures were collected for baseline (n =
35), HF (n = 127), and DMVA (n = 127) states. A single cardiac cycle was selected from
each 2 s ECHO clip for further analysis. Each cycle was defined as the time between
consecutive end-diastolic frames. The LV endocardial boundary was traced from the
posterior mitral valve annulus to the aortic valve annulus (Figure 15), making sure to
avoid tracing trabeculations and muscles. Traces were ideally generated during enddiastole, but some DMVA clips necessitated switching to an intermediate frame to
capture motions accurately.
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Speckle tracking software (Siemens Medical Solutions, Malvern, PA) defined the
endocardial boundary throughout the cardiac cycle given the initial trace. Visual
inspection was used to assess the quality of endocardial tracking. Unacceptable traces
were retraced until a good fit was achieved or the ECHO clip was excluded. A modified
Simpson’s method (translating the 2D LV tracing into a series of disks) was utilized to
compute LV volume for each frame. End-diastolic and end-systolic volumes as well as
ejection fraction were recorded for each tracing. All tracings were conducted by one
individual. Intra-operator variability was assessed by calculating the distance between
averages for specified numbers of tracings (Figure 16). From previous work, somewhere
between 1-10 tracings was considered to represent a single clip. Five tracings (showing a
one-pixel difference compared to the ten-tracing average) was considered acceptable for
this study. All tracings were averaged from their parent clips, with this average clip
considered the basic statistical unit. The example output for a single tracing is displayed
in Figure 17.
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Figure 15 – 4-Chamber Equivalent ICE View : Longitudinal ventricular dynamics were
compared using a probe positioned in the RA to visualize portions of all four chambers.
The red line shows the desired trace of the LV endocardial border.
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Figure 16 - ECHO Intraoperator Error Estimate: Error reduction associated with
incremental increases in the number of traces used to calculate averages for each ECHO
clip. Five tracings were deemed sufficient to characterize each clip given this provided
average values sufficiently similar to the ten-tracing average.

54

Figure 17 – Example ECHO Strain Rate Recording:Longitudinal strain rate waveforms
were generated using speckle-tracking algorithms for each trace during DMVA support.
Diastole is characterized by positive values while systole has negative values.
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Myocardial Function

Myocardial longitudinal strain and strain rates were calculated from the aforementioned
tracings. Raw data for each tracing was measured along 49 points along the trace line.
The standard six regions for the LV 4-chamber ECHO view were calculated by evenly
dividing the 49 trace points. Global strain and strain rates were calculated as the average
of these six regions. To account for uneven sampling rates (since software priority was
given to wall definition), strain and strain rate waveforms were resampled to 100 Hz and
set to a standardized 500 ms cycle. Total strain and peak systolic and diastolic strain rates
were noted for each tracing, again with all five tracing measurements averaged together
to represent a single ECHO clip.

Composite strain and strain rate waveforms were assembled by averaging acceptable
waveforms from each experimental state. Alignment by both systolic and diastolic peaks
was used to facilitate averaging. Systolic peak alignment allowed direct magnitude
comparisons in the systolic phase while revealing relative magnitude and timing
information about the diastolic phase. Diastolic peak alignment provided the same
information but with the phase relationships reversed.
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Dyssynchrony Analysis

Raw strain and strain rate waveforms were used to estimate LV intraventricular
dyssynchrony. DI values are defined as the standard deviation of the time difference
between two cardiac landmarks for every wall region (Figure 18). While many DI
measures use the ECG R-wave as a reference to compare with a strain peak, DMVA
creates considerable mechanical noise that makes capturing quality ECG signals difficult
without substantial filtering. Without a strong ECG component, this study used enddiastole as a reference landmark.

The standard deviation of regional time-to-peak systolic LV strain and strain rates was
utilized to calculate one version of DI. Note that strain and strain rate data were combined
into a single metric for the sake of more practical reporting. A similar analysis was
conducted for diastole to create a combined diastolic peak strain-derived DI metric.
Cross-correlation was used to estimate time delay between a reference strain-based
waveform (extreme basal septum) and the other 48 points along the trace. The standard
deviation of this delay was used to calculate a cross-correlation DI. Finally, the time
delay from end-diastole to minimum LV volume was computed for each of the 49 trace
points. The standard deviation of this delay was used to calculate the LV volume-based
DI metric.
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Figure 18 –Dyssynchrony Index Calculation: DI was calculated using the standard
deviation of time to peak strain/strain rate, minimum LV volume, or delay using crosscorrelation for the entire 49-point trace (each point functions as a region).
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Coordination and Variability

DMVA maximum pneumatic pressure was located for every cycle throughout each 10 s
capture. A device cycle was defined as the time between two adjacent minimum
pressures. Each DMVA cycle’s corresponding hemodynamic peaks were identified
(Figure 19). Aortic flow was chosen as the primary hemodynamic parameter given the
transducers signal strength and quick response time. The time delay between aortic flow
peaks and pneumatic pressure maxima was recorded. While this information may suggest
a mismatch between device and heart signals, it was unknown how much delay naturally
varies from capture to capture. The standard deviation of delay, which will be referred to
as the coordination index (CI), was calculated over the entire 10 s capture to assess
repeatability independent of delay magnitude. Data relationships were evaluated
separately for both VF and HF (Figure 20). Data captures were stratified into five even
quantiles (Q1: 0-20%, Q2: 21-40%, Q3: 41-60%, Q4: 61-80%, Q4: 81-100%) based on
CI (where 100% = least coordination, 0% = most coordination). Pneumatic pressure
waveform characteristics (e.g. maximum pressure and dP/dt) were computed for each
quantile. The magnitude ratio (MR), defined as the ratio of maximum pneumatic pressure
to peak aortic flow, was calculated as a simple measure of efficiency.

Two exceptions to this rule were noted (Figure 21): (1) “skipped” cycles failing to elicit a
response (defined as <5% of the capture’s maximum hemodynamic peak) and (2)
“desynchronized” cycles containing multiple aortic flow peaks. The frequency with
which these exceptions occurred was noted for use in separate metrics, but cycles in these
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categories were excluded from CI calculations because they were not compatible with the
CI formula. The distribution of these exception cycles was compared with normal cycles
included in the CI value.

Statistical Analysis

Values for all parameters were represented as mean ± standard error of mean (SEM)
unless otherwise indicated. One-way ANOVA was run to assess differences between
groups comparing only one variable and post-hoc Tukey’s honestly significant difference
(HSD) tests were used to identify significant differences (p<0.05 unless otherwise noted).
Interaction effects between two independent variables were assessed using two-way
ANOVA and Tukey’s HSD for individual comparisons. Weighted averages were used to
equalize contributions from each animal. Whole waveform comparisons with
standardized cycle lengths periodically tested for significant differences between
experimental states with t-tests.
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Figure 19 – Comparison of DMVA Pneumatic Pressure and Hemodynamic Peaks: (Top)
Location of maximum DMVA pneumatic pressures, (Middle) location of minimum
pressures to define capture cycles, and (Bottom) location of local maxima aortic flow
data points for each cycle. These hemodynamic maxima are paired with corresponding
maximum device pressures for each cycle.

61

Figure 20 - Coordination Index during VF and HF: (Left) Comparison between nearperfect coordination during DMVA VF support and (Right) the more variable nature of
poorer coordination possible during DMVA HF support. Standard deviation of mismatch
between cup pressure and aortic flow maxima was used as a measure of variability.
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Figure 21 – Coordination Index Exception Criteria: Two types of cycles were excluded
from CI calculations: (Left) DMVA failed to elicit a substantial hemodynamic spike (<
5% of cycle hemodynamic maximum) and (Right) multiple hemodynamic peaks located
in one device cycle (desynchronized).
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IV. RESULTS

Aim 1: Determine if pump function is improved toward baseline during DMVA
support of the failing heart.

Rationale: Pump function metrics are the most fundamental characterizations of cardiac
function. DMVA has been shown to substantially boost hemodynamics in the severely
failing heart, although DCC devices can become detrimental if pre-support contractility
is too robust [5,10]. Additionally, neurological perfusion and coronary flows during
DMVA were shown to be superior to continuous flow blood pumps in acute studies. It
has been speculated improved pulsatility during DMVA may account for this enhanced
perfusion [11]. For this reason, both overall hemodynamics and pulsatility were
compared between baseline (representing physiologic blood flow), HF of varying
severity, and DMVA support during HF.

Average Hemodynamics

Results: Aortic flow averages for all accepted 10 s data captures revealed an overall
attenuation during DMVA support compared to baseline and HF (Table 7). Average
DMVA aortic pressures were also reduced compared to baseline but equivalent to nonsupport HF. However, average DMVA maximum LV pressures were equivalent to
baseline and superior to non-support HF. Average measures of pulsatility (Table 8)
showed enhanced values during DMVA compared to either baseline or unsupported HF.
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Discussion: DMVA displayed an overall reduction in aortic hemodynamics compared to
baseline and at best an equivalence to HF. Interestingly, DMVA-generated LV pressures
were similar to baseline and superior to HF. Documented limitations to ventriculararterial coupling using DCC may have been responsible for decreases in mean aortic
hemodynamics while preserving LV pressure [16,18]. The degree of hemodynamic
augmentation was speculated to be determined by baseline myocardial contractility,
inherent afterload resistance, and the preload shift of a typical DCC device [51].

Despite somewhat diminished aortic hemodynamics, common measures of aortic
pulsatility (particularly SHE) were enhanced by DMVA compared to either baseline or
HF. Pulsatility metrics can be fundamentally considered a ratio between pulsatile and
continuous flow signal components. Decreases in the continuous flow component
(average aortic hemodynamics) during DMVA were relatively minor compared to the
large increase in the pulsatile component. This suggested the mechanism of DMVA, and
perhaps DCC in general, significantly augmented pulsatility.
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Table 7 – Hemodynamic Summary for Baseline, HF, and DMVA: DVMA displayed
reduced overall aortic hemodynamics compared to baseline and HF (only cardiac output).
However, LV pressures were not similarly reduced during DMVA support. Values
represented as Mean ± SEM; ap<0.05, vs. Baseline, bp<0.05, vs. HF.

Average Hemodynamics (All Data)
Baseline
HF

DMVA (HF)

Mean Aortic Flow
(L/min)

2.67 ± 0.20

2.13 ± 0.07

a

1.59 ± 0.03

ab

Max Aortic Flow
(L/min)

9.05 ± 0.70

6.82 ± 0.20

a

6.15 ± 0.10

ab

Stroke Volume
(ml)

22.2 ± 1.8

15.3 ± 0.5 a

12.8 ± 0.3 ab

Max LV Pressure
(mmHg)

86.8 ± 4.5

85.0 ± 3.1

91.5 ± 1.5 b

Systolic Pressure
(mmHg)

103.0 ± 5.7

83.7 ± 1.8 a

85.1 ± 1.1 a

MAP (mmHg)

80.7 ± 5.4

67.7 ± 1.7

64.4 ± 1.0 a

Diastolic Pressure
(mmHg)

64.1 ± 4.5

52.1 ± 1.6

(+) dP/dt
(mm Hg/s)

513 ± 27

313 ± 12

(-) dP/dt
(mm Hg/s)

-373 ± 24

-236 ± 10
a

a

49.0 ± 0.9

a

414 ± 8

a

ab

-379 ± 7
b

a

b

Values represented as Mean ± SEM; p<0.05, vs. Baseline, p<0.05, vs. HF
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Table 8 – Pulsatility Metrics Summary for Baseline, HF, and DMVA: DMVA appeared to
boost pulsatility to at least equivalence with baseline when applied to the failing heart.
Values represented as Mean ± SEM; ap<0.05, vs. Baseline, bp<0.05, vs. HF.

Pulsatility Measure Averages (All Data)
Baseline

HF

PP (mm Hg)

44.6 ± 1.8

35.8 ± 1.2

EEP (mm Hg)

91.7 ± 5.9

77.8 ± 1.8 a

81.4 ± 1.0

SHE (ergs/ cm )

14444 ± 1312

13186 ± 603

22479 ± 478

PI

0.20 ± 0.03

0.23 ± 0.02

3.51 ± 1.80

PPI

0.88 ± 0.12

1.12 ± 0.09

15.29 ± 8.28

3

a

DMVA (HF)

a

45.3 ± 0.6

b

b

ab

ab

Values represented as Mean ± SEM; p<0.05, vs. Baseline, p<0.05, vs. HF
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ab

Flow-Stratified Hemodynamic Comparisons

Results: Aortic hemodynamics in the near-physiologic flow category (defined as >75%
mean baseline aortic flows) are displayed in Table 9. DMVA aortic flows were lower
than baseline (by definition) in this category but equivalent to HF. Aortic pressures
during DMVA from this category were equivalent to baseline and superior to HF.
Grouping pulsatility metrics by flow category (Table 10) showed DMVA was at least
equivalent to baseline in this highest flow category while superior to HF across all flow
measures. A trend of increasing SHE, PI, and PPI was generally observed with
decreasing mean flow during DMVA support (which was not observed in non-support
HF). Aortic power integral grouped by flow category showed reductions in DMVA and
HF compared to baseline (Figure 22). DMVA and HF aortic power integrals were
relatively similar except for higher DMVA values in the near-physiologic flow category.

Discussion: Given the range of device settings and potential for variance in underlying
HF, the disparity in support outcomes is hardly surprising. Substantial DMVA
representation in the highest flow category (>75% baseline aortic flow) demonstrated
DMVA’s capability to generate near-physiologic hemodynamics. Given aortic pressures
were similar to baseline in the near-physiologic category, if would appear the limiting
factor for support is aortic flow. The range criteria for this flow group was chosen to
match limitations of DCC devices for improving flow once pre-support aortic flows
reached 70-80% baseline [16,18]. This phenomenon was similarly observed in this study
(Figure 23) where the device had a negative effect on aortic flows with underlying HF
>70% baseline flows. This derogatory effect was not observed with respect to either
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hemodynamic pressures (Figure 24) or strain-based metrics until near 100% baseline
function. Given the relative dearth of knowledge about of DCC in general, trends
promoting superior hemodynamic outcomes should receive further attention.

Relatively high HF aortic flows (Table 9) without DMVA suggested insufficient HF
dysfunction may have contributed to less effective support and diminished output in some
DMVA captures. While additional time in VF before the support period could have
produced more severe HF, this may have further compromised survival given the
exclusion of multiple animals due to premature death or refractory VF. It should also be
mentioned better aortic flow augmentation during DMVA does not necessarily guarantee
superior flows. Hemodynamics are a combination of inherent cardiac function via
myocardial contraction and imposed function via external support. Support of the
extremely impaired heart means most cardiac function is coming from these imposed
forces. The limits of pumping the heart externally restrict the achievable maximum flow
in these instances. Alternatively, declines during external support of high function HF
were likely caused by negative interactions between robust native myocardial function
and DCC. Ideal conditions for DCC support likely remain between these two extremes
(40-70% baseline function during HF).

DMVA was shown to maintain superior pulsatility compared to HF under all flow
conditions even with similar aortic power integrals. Additionally, DMVA’s SHE
significantly improved as overall aortic flow was reduced during support. Given a similar
trend was not strongly observed during non-support HF, it would appear DMVA was
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capable of preserving pulsatile energy even with sharply declining mean flows. These
findings suggested an important feature of DMVA (and possibly DCC in general) is the
ability to preserve pulsatile perfusion even during severe HF. DMVA-generated
pulsatility was shown to be at least equivalent to baseline even with statistically inferior
hemodynamics during DMVA. How DMVA’s manipulation of the native heart structure
improves pulsatility, at least nominally superior to that of the physiologic heart, deserves
further study.
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Table 9 – Near-Physiologic Aortic Flow Hemodynamic Summary. While DMVA aortic
flows were lower than baseline (given the >75% condition), DMVA aortic pressures were
equivalent to baseline and superior to HF. Values represented as Mean ± SEM; ap<0.05,
vs. Baseline, bp<0.05, vs. HF.

Hemodynamic Averages (>75% Baseline Flow)
Baseline

HF

DMVA (HF)

Mean Aortic Flow
(L/min)

3.06 ± 0.10

2.83 ± 0.08

2.64 ± 0.05 b

Max Aortic Flow
(L/min)

10.33 ± 0.41

8.66 ± 0.23 a

9.19 ± 0.16 a

Stroke Volume (ml)

25.4 ± 1.2

18.5 ± 0.8 a

21.9 ± 0.5 ab

Systolic Pressure
(mmHg)

107.5 ± 6.1

91.3 ± 2.6

MAP (mmHg)

84.6 ± 5.8

76.8 ± 2.3

Diastolic Pressure
(mmHg)

67.3 ± 4.9

60.7 ± 2.5

(+) dP/dt

513 ± 27

307 ± 19

(-) dP/dt

-373 ± 24

-225 ± 17
a

a

b

110.3 ± 2.2
86.7 ± 1.8

b

69.5 ± 1.6

a

539 ± 22
a

b

-437 ± 20
b

b

Values represented as Mean ± SEM; p<0.05, vs. Baseline, p<0.05, vs. HF

71

Table 10 - Pulsatility Summary by Mean Aortic Flow Category: DMVA generated
superior pulsatility to HF for all flow levels and was at least equivalent to baseline in the
near-physiologic (>75+) condition. Values represented as Mean ± SEM; ap<0.05, vs.
Baseline, bp<0.05, vs. HF.
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Figure 22 – Aortic Power Integral by Mean Aortic Flow Category: Both DMVA and HF
aortic power integrals were reduced compared to baseline for all flow categories. Values
were similar between HF and DMVA except for higher DMVA integrals in the nearphysiologic (>75%) flow category. Values represented as Mean ± SEM; ap<0.05, vs.
Baseline, bp<0.05, vs. HF.
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Figure 23 – Change in Aortic Flow during HF Support Based on Native Function: The
change in aortic flow (Top) after device application and (Bottom) after device removal
relative to unsupported HF. Similar to observations of DCC devices in general, DMVA
had a negative effect on aortic flow when placed on relatively healthy hearts and only
produced a benefit once a pathological threshold was reached (~70%). Note: The moniker
of underlying HF was used even in cases of physiologic hemodynamics because the heart
was still in a pathologic state due to periods of VF. Taking the device off appeared to
result in more robust hearts as non-device function was attenuated above the 60-70%
threshold. Unless otherwise specified, all measures of underlying function during should
be considered a combination of data just after device placement and just before device
removal.
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Figure 24 - Change in Blood Pressures during HF Support Based on Underlying
Function: Change in (Top) LV pressure and (Bottom) aortic pressure during DMVA
relative to underlying function in nearby non-support data captures. Deficits were only
noted starting at 90-100% of baseline function.
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Aim 2: Determine if myocardial stretch is altered during DMVA
support of the failing heart.

Rationale: Traditional measures of pump function are limited when trying to evaluate
tissue function and health. The volume of blood pumped is only indirectly related to the
contractile properties of the heart muscle itself. Speckle-tracking offers a practical tool
for characterizing myocardial wall dynamics. This technique was utilized to calculate
strain and strain rate peak magnitudes during DMVA support [7]. Common practice
dictates average strain and strain rates are reported in terms of peaks magnitudes
[69,73,99]. However, peak metrics discard most of the strain/strain rate waveform and
potentially valuable information characterizing support. The use of composite strain and
strain rate waveforms allowed for time-based assessments of DMVA mechanics.

Dynamic Morphology and Peak Wall Motions

Results: Estimates of cardiac morphology (Table 11) remained relatively similar between
baseline and DMVA. HF data displayed mildly elevated end-diastolic volumes with
noticeable reductions in stroke volume and ejection fraction. Peak longitudinal LV strain
magnitudes (Table 12) were attenuated during HF relative to either baseline or DMVA.
Additionally, DMVA augmented strain in the failing heart to levels exceeding baseline.
Peak systolic (Table 13) and diastolic (Table 14) longitudinal LV strain rate magnitudes
displayed similar patterns to peak strain. Global strain and strain rates stratified by
underlying HF strain (Table 15) showed attenuated wall motions in the 0-33% baseline
group while higher-functioning categories were relatively indistinguishable.
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Discussion: The longitudinal axis was considered optimal for characterizing cardiac
dynamics [99]. ICE was necessary to acquire high-quality ECHO due to other ultrasound
modalities needing to cross DMVA’s air interface. The 4-chamber long-axis view
presented in this study was the default obtained with an intravascular probe positioned in
the right atrium. While possible to achieve short-axis views with ICE to measure the
radial or circumferential plane, the longitudinal plane was felt to most accurately
characterize overall cardiac stretch throughout the LV. The radial symmetry of the device
would suggest relatively uniform compression through short-axis planes (although some
differences may manifest based on ventricular geometry and wall thickness). However,
the non-uniform nature of longitudinal axis compression makes this plane the most
pertinent to proper device characterization.

End-systolic and end-diastolic volume estimates during DMVA did not appear to differ
markedly from baseline. Predictably, HF systolic function via stroke volume and ejection
fraction was substantially attenuated. The right shift in volumes suggested the heart was
compensating for reduced output by increasing preloads, a trend that was eliminated
during DMVA. The relatively low ejection fraction values (compared to clinical values)
for all states may have been an artifact of the unique view using ICE, but the comparisons
between states fell within expectations.

It was apparent DMVA substantially boosted cardiac strain when applied to the failing
heart. Pathologically attenuated strain was improved to even beyond baseline levels
during DMVA support. DMVA almost doubled the magnitude of LV strain and strain
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rates once placed over the failing heart, demonstrating imposed strain can significantly
boost cardiac motions. In traditional analyses strain is a proxy measurement of myocyte
stretch while strain rate is a proxy measurement for compressive force. It is unclear
whether there is a fundamental difference in effect between imposed strain applied at the
heart’s surface and inherent strain generated by muscle fibers.
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Table 11 – LV Morphologic Changes: While DMVA and baseline maintained relatively
similar morphologic parameters, HF values were pathologically altered. Values
represented as Mean ± SEM; ap<0.05, vs. Baseline, bp<0.05, vs. HF.

Morphological Measures
Baseline

HF

DMVA

EDV (ml)

46.6 ± 0.9

48.7 ± 0.4

a

46.4 ± 0.5

b

ESV (ml)

27.6 ± 0.7

36.3 ± 0.4

a

27.7 ± 0.4

b

SV (ml)

19.1 ± 0.6

11.8 ± 0.3

a

17.1 ± 0.3

ab

EF (%)

40.8 ± 1.0

24.8 ± 0.5 a
a

39.3 ± 0.6 b

Values represented as Mean ± SEM; p<0.05, vs. Baseline,
b

p<0.05, vs. HF.
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Table 12 – Peak LV Longitudinal Strain Magnitudes by State: HF peak strain was
uniformly lower than baseline or DMVA. DMVA generated higher strains than baseline in
all regions. Values represented as Mean ± SEM; ap<0.05, vs. Baseline, bp<0.05, vs. HF.
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Table 13 – Peak LV Longitudinal Systolic Strain Rate Magnitudes by State: HF peak
systolic strain rates magnitudes were uniformly lower than either baseline or DMVA.
DMVA systolic strain rates were higher magnitude than baseline in all regions. Values
represented as Mean ± SEM; ap<0.05, vs. Baseline, bp<0.05, vs. HF.

Wall

Free Wall

Septal

LV Longitudinal Systolic Strain Rate (1/s) by State
State
Region
Baseline
HF
DMVA
Base

-0.96 ± 0.04

-0.84 ± 0.02

-1.36 ± 0.03 ab

Mid

-0.92 ± 0.04

-0.74 ± 0.02 a

-1.34 ± 0.03 ab

Apical

-1.05 ± 0.04

-0.78 ± 0.02 a

-1.51 ± 0.04 ab

Base

-0.89 ± 0.04

-0.67 ± 0.02 a

-1.32 ± 0.03 ab

Mid

-1.04 ± 0.05

-0.61 ± 0.01 a

-1.33 ± 0.03 ab

Apical

-1.02 ± 0.04

-0.78 ± 0.02 a

-1.60 ± 0.04 ab

Global

-1.07 ± 0.03

-0.80 ± 0.01 a

-1.50 ± 0.02 ab

Global (%
Baseline)

-98 ± 3

-76 ± 1 a

-146 ± 3 ab

Values represented as Mean ± SEM; ap<0.05, vs. Baseline, bp<0.05, vs. HF
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Table 14 - Peak LV Longitudinal Diastolic Strain Rate Magnitudes by State: HF peak
diastolic strain rates magnitudes were uniformly lower than either baseline or DMVA.
DMVA systolic strain rates were higher magnitude than baseline in all regions. Values
represented as Mean ± SEM; ap<0.05, vs. Baseline, bp<0.05, vs. HF.
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Table 15 – Global Peak LV Longitudinal Strain and Strain Rate Magnitudes by
Underlying Function: Underlying function was established for each DMVA ECHO clip
by characterizing a nearby non-support clip (either just before device installation or just
after device removal) relative to baseline. Severely failing hearts (0-33%) displayed
attenuated wall motions compared to higher-functioning hearts (which were relatively
similar). Values represented as Mean ± SEM; 1p<0.05, vs. 0-33%, 2p<0.05, vs. 33-66%,
p<0.05, vs. 66-100%.
DMVA LV Longitudinal Wall Motion Metrics by Underlying Function
Peak Strain or Strain Rate during HF Period without DMVA
(Relative to Baseline)

Strain-Based Parameters during
DMVA Support

3

Strain

Systolic
Strain Rate

Diastolic
Strain Rate

0-33%

33-66%

66-100%

100%+

Global (%)

15.5 ± 0.6

18.6 ± 0.5 1

18.5 ± 0.5 1

18.3 ± 0.8

Global (%
Baseline)

105 ± 7

132 ± 4 1

138 ± 4 1

144 ± 5 1

Global (1/s)

-1.21 ± 0.11

-1.55 ± 0.04 1

Global (%
Baseline)

108 ± 4

127 ± 4 1

128 ± 4 1

126 ± 5 1

Global (1/s)

1.30 ± 0.11

1.52 ± 0.04

1.57 ± 0.05

1.52 ± 0.05

Global (%
Baseline)

108 ± 7

130 ± 3 1

141 ± 4 1

142 ± 5 1
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-1.48 ± 0.04 12 -1.49 ± 0.05 123

Composite Strain and Strain Rate Waveforms

Results: Average global strain waveforms aligned by diastolic peak (Figure 25) further
emphasized the attenuation observed during HF. DMVA augmentation during HF
exceeded both baseline and HF throughout the entire composite waveforms. Average
global longitudinal strain rate waveforms aligned by diastolic peaks (Figure 26) displayed
similar attenuation during HF and relatively good alignment between baseline and
DMVA (as evidenced by the lack of significant differences). Substantial DMVA
augmentation compared to non-support HF was also observed with strain rate alignment
by systolic peak (Figure 27). However, diastolic strain rates were dramatically higher
during early diastole compared to baseline.

Discussion: Strain and strain rates have traditionally been reported as peak magnitudes.
While yielding quantitative estimates of stretch and contractility, this approach also
encourages excessive generalization. Singularly using peak data discards most of the
waveform and may obscure timing trends which would be prominent in whole-waveform
comparisons. While these relationships could be quantified with a multitude of new
parameters, waveform cycles were compared visually to facilitate better comprehension.
This process required resampling isolated cycles (for each 10 s capture) to a standard
length. Cycles were then aligned in separate analyses by either systolic or diastolic peak
to enable direct averaging. Data opposite the aligned peak should be considered relative
magnitudes that reveal information about timing events. Once aligned, mean cycles were
averaged by state and compared.
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DMVA was able to augment strain and strain rates during HF to at least baseline
physiology. Given the potential for externally-imposed forces to generate unnatural strain
patterns, the relative similarities between DMVA and baseline waveforms suggested
actuating the native heart structure may inherently produce a degree of biofidelity. While
these observations are currently limited to the longitudinal axis of the 4-chamber ICE
view, the results speak to the possibilities for DCC to induce physiologic, perhaps even
hyperdynamic, stretch and compression in the failing LV. DMVA’s ability to augment
strains and strain rates did not appear to be substantially impacted by the degree of
underlying HF (at least as defined by HF strain). This information, coupled with the
stratified data in Table 15, suggested the primary distinction in the degree of strain and
strain rate augmentation was between VF (minimal functionality) and HF.

The only major difference between DMVA and baseline timing effects was DMVA’s
early diastolic augmentation. Note DMVA and baseline strain rate waveforms were near
identical after this initial divergence. Diastolic actuation during DCC is much harder to
achieve than systolic actuation as diastolic retraction requires an attachment mechanism.
Without proper attachment, the reverse motion of the device after inward compression
will not pull out the compressed ventricles. DMVA uses an apical vacuum to create a seal
between the heart and device membrane that theoretically allows the device to retract the
ventricles. However, this active assist appeared to be limited to early diastole and may
signal a breakdown in the attachment mechanism at a certain point of retraction.
Logically, fully maintained attachment would enable full retraction of the cardiac wall
(assuming an incompressible wall) to the semi-rigid outer shell and augment end-
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diastolic volumes beyond baseline physiology. The agreement of end-diastolic volumes
between DMVA and baseline suggested diastolic assist may functionally cease after
achieving physiologic volumes. While future studies should further investigate the poorly
understood topic of diastolic assist during DCC, the potential of the mechanism is
apparent for augmenting early diastolic function.
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Figure 25- Composite LV Global Systolic Strain Comparisons: Trace averages were
aligned by diastolic peak (0% strain) for each state. Baseline captures were acquired
before the first VF period while HF and DMVA captures were acquired in
chronologically adjacent pairings (the DMVA composite waveform was a combination of
captures just after support was initiated and just before device removal). DMVA
substantially augmented strain relative to either baseline or HF at all time points along the
standardized cycle. Values represented as Mean ± SEM. A black bar denotes statistical
differences between the specified states at the time specific time locations within the
standardized cycle time (▀ p<0.05).
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Figure 26- Composite LV Global Systolic Strain Rate Differences during DMVA: Trace
averages were aligned by diastolic strain rate peak. Differences between DMVA and
baseline and DMVA and HF were calculated (with a positive value signifying higher
DMVA systolic strain rates). Comparison of relative magnitudes in the systolic phase
revealed relatively good agreement between DMVA and baseline. Values represented as
Mean ± SEM. A black bar denotes statistical differences between the specified states at
the specific time locations within the standardized cycle time (▀ p<0.05).
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Figure 27 - Composite LV Global Diastolic Strain Rate Differences during DMVA: Trace
averages were aligned by systolic strain rate peak. Differences between DMVA and
baseline and DMVA and HF were calculated (with a positive value signifying higher
DMVA diastolic strain rates). DMVA substantially augmented HF throughout most of the
cycle. DMVA was relatively similar to baseline except for an early diastolic boost during
support. Values represented as Mean ± SEM. A black bar denotes statistical differences
between the specified states at the specific time locations within the standardized cycle
time (▀ p<0.05).
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Figure 28 - Composite LV Global Diastolic Strain Rate Differences during DMVA by
Underlying HF Strain: Trace averages were aligned by systolic strain rate peak
Differences between DMVA and baseline were calculated (with a positive value
signifying higher DMVA diastolic strain rates). While the early diastolic boost was
present in every group, no differences were detected based on changes in underlying
strain rates.
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Figure 29 - Composite LV Global Diastolic Strain Rate Differences during DMVA by
Underlying Function: Trace averages were aligned by systolic strain rate peak.
Differences between DMVA and HF were calculated (with a positive value signifying
higher DMVA diastolic strain rates). Only minor differences were detected between
comparisons with the 33-66% strain group. Values represented as Mean ± SEM. A black
bar denotes statistical differences between the specified states at the specific time
locations within the standardized cycle time (▀ p<0.05).
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Aim 3: Determine if DMVA support of the acutely failing heart
improves ventricular mechanical synchrony.

Rationale: External support has the capacity to alter the timing of perceived ventricular
contraction by imposing an irregular force profile to the heart surface beyond that
normally seen in the thoracic cavity. During DMVA HF support, heart motions are
dictated by a combination of externally imposed forces and inherent contractility. It is
unknown how these, by definition, unnatural external forces may alter cardiac contractile
timing. In some speculative literature, DMVA has been criticized for the “inverted” shape
purportedly imposed by device construction [30]. However, it remains unknown if nonuniform longitudinal actuation significantly alters timing in a meaningful way.

Intraventricular Dyssynchrony
Results: Four different DI averages were compared by experimental state (Table 18): (1)
standard deviation of delay between waveforms assessed by cross-correlation, (2)
standard deviation of time from end-diastole to systolic strain/strain rate peaks, (3)
standard deviation of time from end-diastole to diastolic strain/strain rate peaks, and (4)
standard deviation of time from end-diastole to minimum LV volume. Overall, slight
differences existed between HF and DMVA while baseline tended to have the lowest
dyssynchrony values. Stratifying data further with underlying HF strain (Tables 19-22)
revealed a weak trend of greater DI differential between states with more underlying
heart function. Most HF strain groups could generally be characterized by a baseline <
HF < DMVA dynamic for DI values.
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Discussion: Variants of DI showed a general trend for DMVA’s DI to be higher than
baseline and HF, although this increase was not always significant. Given the method of
external compression, it is perhaps unsurprising DMVA adds some degree of
dyssynchronous movement. However, this increase appeared to be largely transient as
dyssynchrony during HF was reduced upon device removal. It is unknown if deviceimposed dyssynchrony during support has any long-term effects on cardiac recovery
given the acute timeframe of these experiments.

There is little agreement on how to measure dyssynchrony. DI is typically the standard
deviation of the time delay between two landmarks (e.g. the QRS wave and peak strain),
but landmarks vary based on the needs of the study. Mechanical noise in the ECG signal
necessitated the end-diastole reference metric used to quantify dyssynchrony in this study
Results can also vary based on the precise ultrasound plane analyzed, foreshortening,
probe type, image quality, use of velocity or strain, and many other factors. This variation
and choice of reference region may explain why DI values were higher than those seen in
the relatively narrow applications in clinical practice.

The baseline < HF < DMVA relationship for DI values (with higher values denoting
more dyssynchrony) was primarily observed in higher functioning HF. This effect was
muted in more severe HF to the point where values were statistically indistinguishable
between states. While there was little difference within each state based on underlying
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strain, more robust hearts contributed to higher dyssynchrony during support compared to
other states.

Cross-correlation is generally a useful tool for matching up waveforms in time [1,80].
The time shift needed to produce the most overlap between two waveforms is considered
the delay. The standard deviation of this delay was used as a DI calculation. As opposed
to peak-to-peak differences, cross-correlation makes use of the entire waveform to
determine delay. Despite these positive features, cross-correlation DI had the highest
variance of any DI metric. This may suggest inconsistencies in regional waveform shapes
within each ECHO tracing.
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Table 16 - Average DI Values during Baseline, HF, and DMVA: DI was calculated from
the standard deviation of (1) cross-correlation derived delay between strain/strain rate
waveforms, (2) time to systolic peak strain/strain rate, (3) time to diastolic peak
strain/strain rate, and (4) time to minimum LV volume. All metrics showed somewhat
elevated DMVA values relative to baseline and HF. Values represented as Mean ± SEM;
a

p<0.05, vs. Baseline, bp<0.05, vs. HF, 1p<0.05, vs. 0-33%, 2p<0.05, vs. 33-66%,

3

p<0.05, vs. 66-100%.
Dyssynchrony Metric by Experimental State
State
Dyssynchrony Metric

Baseline

HF

DMVA

Cross-Correlation
(ms)

117 ± 4

120 ± 2

125 ± 2

Systolic DI (ms)

128 ± 1

134 ± 1

138 ± 1 b

Diastolic DI (ms)

126 ± 2

134 ± 1 a

137 ± 1 ab

LV Volume DI (ms)

70 ± 3

113 ± 2 a

121 ± 2 ab
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Table 17 Average Cross-Correlation DI Values during Baseline, HF, and DMVA by
Underlying Strain Relative to Baseline. No differences were detected due to high
variance. Values represented as Mean ± SEM; ap<0.05, vs. Baseline, bp<0.05, vs. HF,
1

p<0.05, vs. 0-33%, 2p<0.05, vs. 33-66%, 3p<0.05, vs. 66-100%.

Average Cross-Correlation DI (ms) by Underlying Strain
Global Strain without DMVA
(Relative to Baseline)
State

0-33%

Baseline

33-66%

66-100%

100%+

126 ± 9

116 ± 7

113 ± 6

HF

119 ± 5

118 ± 3

124 ± 4

120 ± 6

DMVA

140 ± 6

115 ± 3

129 ± 3

126 ± 5
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Table 18 - Average Systolic Strain DI Values during Baseline, HF, and DMVA by
Underlying Strain Relative to Baseline. Higher underlying function was correlated with a
more pronounced baseline < HF < DMVA relationship. Values represented as Mean ±
SEM; ap<0.05, vs. Baseline, bp<0.05, vs. HF, 1p<0.05, vs. 0-33%, 2p<0.05, vs. 33-66%,
3

p<0.05, vs. 66-100%.

Average Systolic Strain DI (ms) by Underlying Strain
Global Strain without DMVA
(Relative to Baseline)
State

0-33%

Baseline

33-66%

66-100%

100%+

128 ± 3

126 ± 2

126 ± 2

HF

137 ± 2

132 ± 1

134 ± 1

137 ± 2

DMVA

141 ± 2

132 ± 1 1

139 ± 1 2

141 ± 2 a 2
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Table 19 Average Diastolic Strain DI Values during Baseline, HF, and DMVA by
Underlying Strain Relative to Baseline. Higher underlying function was correlated with a
more pronounced baseline < HF < DMVA relationship. Values represented as Mean ±
SEM; ap<0.05, vs. Baseline, bp<0.05, vs. HF, 1p<0.05, vs. 0-33%, 2p<0.05, vs. 33-66%,
3

p<0.05, vs. 66-100%.

Average Diastolic Strain DI (ms) by Underlying Strain
Global Strain without DMVA
(Relative to Baseline)
State

0-33%

Baseline

33-66%

66-100%

100%+

132 ± 3

127 ± 2

126 ± 2

HF

136 ± 2

132 ± 1

135 ± 1

136 ± 2

DMVA

141 ± 2

135 ± 1

141 ± 1 a 2

140 ± 2 a
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Table 20 Average LV Volume DI Values during Baseline, HF, and DMVA by Underlying
Strain Relative to Baseline. Higher underlying function was correlated with a more
pronounced baseline < HF < DMVA relationship. Values represented as Mean ± SEM;
a

p<0.05, vs. Baseline, bp<0.05, vs. HF, 1p<0.05, vs. 0-33%, 2p<0.05, vs. 33-66%,

3

p<0.05, vs. 66-100%.

Average Volume-Derived DI (ms) by Underlying Strain
Global Strain without DMVA
(Relative to Baseline)
State

0-33%

Baseline

33-66%

66-100%

100%+

81 ± 10

71 ± 5

65 ± 5

HF

126 ± 5

109 ± 3

114 ± 4 a

109 ± 6 a

DMVA

123 ± 6

113 ± 3 a

125 ± 3 a

130 ± 5 a
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Localized Time Differences

Results: Analyzing whole-trace (all 49 points) peak strain absolute time delays (relative
to an extreme basal septal reference) showed DMVA time differences were primarily
localized to the free-wall on the apical and apical mid walls compared to HF (Figure
30A). The same comparison with baseline showed an opposite trend of localization to the
septal apical and apical mid walls (Figure 30B). A similar analysis for strain rates showed
earlier compression in the apical half of the LV during DMVA compared to baseline
(Figure 31B). This trend was made more apparent when testing for near significance
using a statistical range of 0.05<p<0.01. Minor early contraction in the apical mid-wall
was observed for the comparison between DMVA and HF (Figure 31A).

Discussion: Disaggregating the whole-trace strain DI by each individual systolic peak
time difference revealed wall locations where DMVA significantly impacted cardiac
timing. Almost all differences were localized to the apical half of the LV wall, suggesting
DMVA’s maximum effect is experienced primarily in the apical and mid-wall regions
(particularly at mid-wall/apical border). DMVA strain time differences being localized to
the septal wall, relative to baseline, could originate from greater RV actuation during
DMVA. DMVA applies a uniform LV-relevant pressure to both ventricles, which leads to
non-pathologic over-actuation of the RV. Literature calculations have suggested that a
large pressure differential is necessary to maintain balanced pump function, but the LV
value of 340 mm Hg was unreasonably high for DMVA operation [50]. Likewise,
substantial degradation in function was not observed under experimental conditions with
much lower maximum LV epicardial pressures during DMVA. Reduced inherent
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contractility may explain why DMVA timing differences are more prevalent in the free
wall in the comparison with HF. Less forceful inherent contraction may also accentuate
eccentricities imposed directly on the LV free wall and provide less resistance to external
compression.

A similar analysis with strain rates revealed premature motion during DMVA in the apical
and apical mid-walls relative to baseline. Due to decreased variance in strain rate derived
values, contraction was confirmed to occur earlier during DMVA support at the specified
locations. It should be noted two different actuation profiles are possible depending on
device dimensions and fit. An inversion (hourglass) pattern is more prominent when
maximum compression occurs in the mid-wall (Figure 32A) while apical maximum
compression generates motion toward the base (Figure 32B). Given timing differences
predominated in the apical regions, it would seem reasonable to suggest the apical
displacement pattern predominates as a pumping mechanic in this study.
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Figure 30 – Localized Strain Timing Differences: Map showing peak strain time
magnitude differences (relative to a septal basal reference) induced by DMVA for a 49point trace relative to (A) HF and (B) baseline. Numbered markers indicate a significant
increase in delay magnitude during DMVA relative to the specified non-DMVA state.
DMVA produced timing differences between the mid and apical free walls and the apical
septal wall relative to HF. DMVA generated timing differences only in the mid and apical
septal wall relative to baseline.
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Figure 31 – Localized Strain Rate Timing Differences: Map showing systolic peak strain
rate time differences (relative to a septal basal reference) induced by DMVA for a 49point trace relative to (A) HF and (B) baseline. Numbered markers indicate significantly
(p<0.05) early contraction due to DMVA relative to the specified non-DMVA state. A
blue line signified a near-significant difference (0.05<p<0.01). DMVA produced timing
differences in the apical mid-walls relative to HF. Timing differences were observed
mostly in the apical regions relative to baseline.
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Figure 32 - Example Systolic and Diastolic LV Traces during Support of the Failing
Heart. (A) Ventricular inversion primarily focused on the mid-wall. (B) Minimal
inversion with more apical displacement in the basal direction.
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Aim 4: Determine if DMVA support interacts with the acutely failing
heart to alter hemodynamic variability.

Rationale: It has been acknowledged externally-imposed cardiac stretch can facilitate
mechanical pacing [28,94-95]. However, most modern testing has been conducted with in
vitro cell-stretching rigs or ex vivo indenters on the heart surface [31,67,96]. The goal of
this study was to develop an appropriate measure to assess in vivo mechanical pacing via
variability between the mechanical stimulus and hemodynamic result. This measure was
used to assess the effectiveness of electrically unpaced external support using DMVA and
how it may facilitate coordination between the device and heart.

DMVA Coordination during Failure

Results: The CI distribution for DMVA support during HF and VF (Figure 33) showed
the majority of VF data having CI < 1 ms while HF data was more widely distributed.
DMVA 10 s captures during HF support were divided into five equal quantiles based on
CI (Table 23). Mean aortic flows and MR values appeared to be unaffected by CI
quantile while peak aortic flows declined with increasing CI. Mean time delay between
peaks and both exclusion criteria (skipped and unsynchronized cycles) were substantially
enhanced with increasing CI. DMVA 10 s captures during VF were also divided into five
equal quantiles based on CI (Table 24). Quantiles C1-C4 maintained relatively similar
values while C5 had higher aortic flows, lower MR values, greater mean delay between
peaks, and increased incidence of both exclusion criteria. Analysis of aortic power
integral for HF support (Figure 34) revealed no difference when comparing CI values,
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although integrals during HF were substantially boosted compared to the VF average.
The effect of underlying HF aortic flow on coordination during DMVA showed increases
in CI and unsynchronized cycles with increasing underlying heart function. (Table 25).
The incidence of unsynchronized cycles by CI during HF support (Figure 35) revealed
the virtual nonexistence of unsynchronized periods below 15 ms. Conversely, the
accompanying plot of skipped cycles by CI during HF support revealed a steady increase
of skipped cycles starting at 0 ms.

Discussion: Predictably, HF support displayed a more varied CI distribution than VF
data. VF is characterized by a lack of meaningful synergistic contraction that translates
into less intrinsic interference during DMVA support. Given this lack of resistance, the
majority of VF support captures were characterized by a high degree of predictability.
The variability of intrinsic contraction and interference with DMVA likely accounts for
the greater diversity of CI values during HF support. A minority of VF captures displayed
higher CI values more characteristic of HF. Whether this represents an actual transitory
switch to HF during the VF period (few incidences of spontaneous defibrillation were
observed upon device removal) or interference from factors such as respiratory artifact
deserves more attention in future studies. Parameters differed markedly in this C5
quantile compared to C1-C4, suggesting captures with CI > 3 ms during the VF support
period may not adequately represent VF characteristics.

Better coordination during HF support (characterized by lower CI values) was ideal for
the stated purpose of replicating physiologic cardiac contraction. Three potential reasons
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for improved CI during HF support are apparent: (1) failure severe enough to limit
intrinsic contractility in a manner similar to VF, (2) artifact increasing CI calculations,
and (3) mechanical pacing increasing coordination between the device and the heart.
Aortic power integrals (an estimate of pump function) during VF support were noticeably
less than those in HF support due to the loss of meaningful native heart function. There
was no apparent difference in pump function when comparing CI quantiles during HF.
This suggested severe HF was not responsible for improvements in CI. While random
artifact could increase already poor CI values, this would not be expected to produce
identifiable trends related to device operation as seen in this study. Therefore, the most
likely determinant for captures with better coordination remains increased mechanical
pacing.

Higher underlying HF aortic flows were associated with higher CI values during DMVA.
More robust intrinsic heart function was predictably more likely to prevent optimal
coordination between the device and heart without electrical pacing. However, this
relationship should not obscure that every flow group had representation throughout the
entire CI range. The higher CI averages observed with higher intrinsic flows were skewed
by greater instances of gross discoordination. The ultimate purpose of this analysis was to
determine the factors that mitigate discoordination.

It is important to note skipped and unsynchronized cycles were excluded from the CI
calculation. Both types of exception cycles represent a deviation from the CI formula that
would obscure CI results if included. Skipped cycles did not have a demonstrable
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hemodynamic response (<5% maximum aortic peak within each capture) while
unsynchronized cycles had multiple hemodynamic peaks without a clear relationship to
device pressure. However, the incidence of both exception cycle types increased with
higher CI values (meaning less coordination). This suggested conditions that promote
weaker coordination with a 1:1 device to aortic flow peak ratio may more readily
degenerate into skipped or unsynchronized cycles. These exception cycles were
associated with reduced aortic hemodynamics and imposed a significant penalty on heart
function when encountered. Given the detrimental impact on heart function, effort should
be taken to minimize these exception cycles during device operation. While skipped
cycles steadily increased from 0-30 ms, unsynchronized cycles were virtually nonexistent until 15 ms. This further suggested 1:1 ratio cycles needed to reach a particular
CI threshold before devolving into unsynchronized cycles. It should be noted each data
capture consisted of 16 cycles on average. This means that one excluded cycle in the 1015 ms group (6.3% exclusion rate) develops into four excluded cycles in the 25-30 ms
range (25% exclusion rate).
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Figure 33 – Distribution of Coordination Index for VF and HF Support: The majority of
VF support captures were CI < 1 ms while HF captures are more evenly distributed
throughout the intervals.
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Table 21 - Coordination-Relevant Variables during HF Support: Captures were divided
into five quantiles based on coordination. Higher coordination index was associated with
lower peak aortic flows, increasing delay between device/hemodynamic peaks, and
higher incidence of excluded cycles. Trivial values were rounded to zero. Values
represented as Mean ± SEM; ap<0.05, vs. C1, bp<0.05, vs. C2, cp<0.05, vs. C3, dp<0.05,
vs. C4.

Coordination (HF)
Coordination Quantile
C2

C3

C4

Mean Aortic Flow
(L/min)

C1
(Better)
1.60 ±
0.07

1.72 ±
0.08

1.54 ±
0.07

1.67 ±
0.08

C5
(Worse)
1.45 ±
0.1

Peak Aortic Flow
(L/min)

6.98 ±
0.26

6.44 ±
0.24

5.68 ±

5.95 ±

5.28 ±

10.2 ±
0.4
4.9 ±
0.4

12.8 ±
1.6
4.7 ±
0.3
2.1 ±

MR (mm Hg/ml)
Delay (ms)
CI (ms)

0.6 ±
0.03

Periods Skipped

0.01 ±
0.01

0.1 a
0.19 ±
0.13

Periods
Desynchronized

0

0
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ab

a

0.20
10.3 ±
0.4
9.6 ±

0.23
9.2 ±
0.6
16.6 ±

0.20 abd
11.4 ±
1.4
26.8 ±

0.7
6.4 ±

ab

0.6
16.6 ±

abc

0.5
30.1 ±

0.2 ab
0.37 ±
0.09

0.4 abc
1.31 ±

0.4 abcd
2.84 ±

abc

0.01 ±
0.01

0.26
0.87 ±

abc

0.11

0.18
0.38 ±
0.09

abcd

abcd

abcd

Table 22 - Coordination-Relevant Variables during VF Support: Captures were divided
into five quantiles based on coordination. Quantiles C1-C4 were mostly indistinguishable
while quantile C5 took on characteristics reminiscent of HF. Trivial values were rounded
to zero. Values represented as Mean ± SEM; ap<0.05, vs. C1, bp<0.05, vs. C2, cp<0.05,
vs. C3, dp<0.05, vs. C4.

Coordination (VF)
Coordination Quantile
C2

C3

Mean Aortic Flow
(L/min)

C1
(Better)
1.36 ±
0.69

1.26 ±
0.07

1.12 ±

1.44 ±

a

Peak Aortic Flow
(L/min)

5.63 ±
0.26

5.12 ±
0.25

MR (mm Hg/ml)

11.5 ±
0.3

12.3 ±
0.5

0.25
12.4 ±
0.46

0.08 c
5.31 ±
0.23

Delay (ms)

5.8 ±
0.3

5.6 ±
0.4

5.2 ±
0.4

CI (ms)

0.2 ±
0.004

0.4 ±
0.004

0.6 ±
0.01

Periods Skipped

0

0.13 ±
0.11

0.01 ±
0.01

0.1 abc
0.13 ±
0.05

Periods
Desynchronized

0

0

0

0

112

C4

0.06
4.87 ±
a

11.9 ±
0.6
5.7 ±
0.5
2.4 ±

C5
(Worse)
1.84 ±
0.08 abcd
6.22 ±
abc

0.20
7.9 ±

0.6 abcd
15.7 ±
abcd

0.9
17.7 ±

0.9 abcd
1.15 ±
abcd

0.21
0.41 ±

0.10 abcd

Figure 34 – Aortic Power Integrals for Coordination Index Quantiles during HF Support.
Aortic power integral was calculated as the integral of the product of aortic flow and
pressure. While values were substantially boosted from the VF support average, no
differences were observed between CI quantiles during HF support. Values represented as
Mean ± SEM; ap<0.05, vs. C1, bp<0.05, vs. C2, cp<0.05, vs. C3, dp<0.05, vs. C4.
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Table 23 – Effect of Underlying HF on Coordination during HF Support: Captures were
divided into four groups based on underlying HF aortic flow relative to baseline. Less
severe HF was characterized by higher coordination index values and more
unsynchronized periods. Values represented as Mean ± SEM; 1p<0.05, vs. 0-25%,
2

p<0.05, vs. 25-50%, 3p<0.05, vs. 50-75%

Coordination Metrics durin DMVA by Aortic Flow (HF)
Aortic Flow without Device (Relative to Baseline)
Metric

0-25%

25-50%

Coordination
Index (ms)

8.1 ± 1.3

12.7 ± 2.3

15.8 ± 2.0

Periods Skipped

1.25 ± 0.20

0.64 ± 0.12

0.89 ± 0.22

Periods
Desynchronized

0.24 ± 0.09

0.56 ± 0.25
1

50-75%

1.86 ± 0.57
2

75%+
1

12

14.1 ± 1.9

1

0.86 ± 0.19

1.53 ± 0.34

1

Values represented as Mean ± SEM; p<0.05, vs. 0-25%, p<0.05, vs. 25-50%,
3

p<0.05, vs. 50-75%
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Figure 35 –Number of Excluded Periods during HF for Coordination Index Intervals.
Each capture contained 16 cycles on average. Both skipped (DMVA fails to elicit a
hemodynamic response) and unsynchronized (multiple hemodynamic peaks in one device
cycle) cycles generally increased with higher CI. However, unlike skipped periods,
unsynchronized periods were virtually nonexistent below 15 ms.
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DMVA Dynamics Characterized by Coordination Index

Results: Average device parameters were computed with respect to coordination
quantiles for HF and VF support. For HF support, lower CI quantiles were strongly
associated with higher peak support pressures (Figure 36). Conversely, VF support
(Figure 37) did not show a clear relationship between CI and peak pressure (particularly
once the aberrant C5 data was dismissed). Given the relationship found during HF
support, both average +dP/dt (Figure 38) and -dP/dt (Figure 39) during the positive
portion of the pressure cycle were examined. The +dP/dt positive pressure slope was
strongly correlated with CI (in a similar manner to the peak positive pressure) while the
-dP/dt positive pressure slope was not as strongly associated with CI. Comparisons of CI
between different support aortic flow categories for different pressure thresholds did not
show any discernable trends (Table 27).

Discussion: Higher maximum pressures and +dP/dt (during the positive pressure phase)
were both strongly associated with better coordination quantiles during HF support.
Presumably, the greater stretch and more forceful compression that accompanied
increases in device pressure and +dP/dt created better coordination between the device
and heart. However, it is unknown if this effect continues indefinitely with higher
pressures or if increases in coordination diminish once a pressure threshold is reached.
Given the lack of electrical pacing, any increase in coordination likely originated from
the mechanical stimulus. Importantly, an equivalent relationship was not observed during
VF support. The fibrillating heart can be characterized by a significant reduction in
contractility. Without any resistance from inherent function, compression is dictated
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solely by DMVA and can readily generate a single simultaneous hemodynamic peak in
response to device actuation. The relative unimportance of -dP/dt (associated with the
relaxation phase of the device) for promoting coordination during HF suggested the
compressive phase of device actuation was paramount for producing this mechanical
effect. Adequate coordination becomes more necessary with increasing native heart
function given the potential for destructive interference between the device and heart.
While this interference may provide a theoretical limit to hemodynamic augmentation, no
change in mean aortic hemodynamics was observed across CI quantiles during HF
support.
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Figure 36 - Average DMVA Maximum Pressure for Each Coordination Index Quantile
during the HF Support Period: DMVA pressures were segregated into five equal CI
quantile groups. Higher peak pneumatic pressures were strongly associated with more
coordinated groups. Values represented as Mean ± SEM; ap<0.05, vs. C1, bp<0.05, vs.
C2, cp<0.05, vs. C3, dp<0.05, vs. C4.
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Figure 37- Average DMVA Maximum Pressure for Each Coordination Index Quantile
during the VF Support Period: DMVA maximum pressures were segregated into five
equal CI quantile groups. Peak pneumatic pressures (particularly when excluding the C5
quantile) did not dramatically shift with increasing CI in quantiles C1-C4. Values
represented as Mean ± SEM; ap<0.05, vs. C1, bp<0.05, vs. C2, cp<0.05, vs. C3, dp<0.05,
vs. C4.
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Figure 38 – Device Average +dP/dt for Each Coordination Index Quantile during the HF
Support Period: DMVA maximum pressures were segregated into five equal CI quantile
groups. The +dP/dt value was the average pressure slope between zero and maximum
device pressures. Higher systolic +dP/dt was strongly associated with better coordination
quantiles. Values represented as Mean ± SEM; ap<0.05, vs. C1, bp<0.05, vs. C2, cp<0.05,
vs. C3, dp<0.05, vs. C4.
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Figure 39 – Device Average -dP/dt for Each Coordination Index Quantile during the HF
Support Period: DMVA maximum pressures were segregated into five equal CI quantiles
groups. The -dP/dt value was the average pressure slope between maximum and zero
device pressures. Higher -dP/dt was only weakly associated with better CI quantiles.
Values represented as Mean ± SEM; ap<0.05, vs. C1, bp<0.05, vs. C2, cp<0.05, vs. C3,
d

p<0.05, vs. C4.
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Table 24 – Coordination Index for Relative Pressure Groups Stratified by Aortic Flow
during the HF Support Period.: Low relative device pressures were associated with higher
CI. No trend was observed with increasing support aortic flows. Values represented as
Mean ± SEM; ap<0.05, vs. 25-50%, bp<0.05, vs. 50-75%, 1p<0.05, vs. Low, 2p<0.05, vs.
Medium.

Effect of Device Pressure on Coordination Index by Aortic Flow (HF)
Cup Pressure

Aortic Flow during Support (Relative to Baseline)
25-50%

50-75%

75%+

Low

18.71 ± 1.40

19.89 ± 1.16

19.01 ± 2.26

Medium

5.66 ± 0.71 a

9.61 ± 1.10 a

11.09 ± 1.62 a

High

6.55 ± 1.66 a

4.65 ± 0.70 a

7.96 ± 1.26 a
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Effect of Actuation Rate on Ventricular Capture

Results: The distribution of device cycles with only one aortic flow peak showed a
central tendency around the device pressure peak (Figure 40). However, the distribution
of unsynchronized cycles (those with two or more aortic flow peaks for each device
pressure peak) showed two distinct groupings (Figure 40). One grouping preceded the
peak mechanical stimulus while the second grouping trailed behind.

Discussion: Analysis of the effect of changes in actuation rate was limited by the
relatively narrow range of rates used in this study. However, the distribution of
hemodynamic peaks relative to the peak mechanical stimulus for unsynchronized periods
revealed two separate locations. The early peak is of tremendous interest to device
efficacy as it indicated early intrinsic contraction before any significant compression
from the device. The use of physiologic canine heart rates for device efficacy may make
sense from a theoretical perspective, but it may allow for small differences in intrinsic
rate to manifest in the form of early compression.
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Figure 40 - Distributions of Aortic Flow Peaks for the Average Device Cycle. Single
peak captures (1:1 ratio) displayed a central tendency around the peak mechanical
stimulus. Multiple peak captures were characterized by an early peak likely due to
inherent contraction and a later peak following the mechanical stimulus.
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V. CONCLUSIONS
Summary

Aim 1: Does pump function improve toward baseline during DMVA support of the
failing heart?

DMVA demonstrated the potential to improve hemodynamics to physiologic levels, but
the extent of augmentation was highly variable throughout the course of this study.
Averaged measures of pump function showed DMVA support, while sufficient for
supporting the heart, failed to match baseline hemodynamics. Changes in experimental
device settings and interactions with underlying levels of HF are the most probable
sources of this variation. Inherent contractility in the failing heart and imposed strain
from DMVA are generally thought to have an additive impact on hemodynamics.
However, this effect appeared to become detrimental when the device is placed over
more robust hearts (70-80% baseline function), presumably due to mismatched LVarterial coupling. Regardless of trends in mean hemodynamics, DMVA produced
superior pulsatility relative to either HF or baseline. Given the similar nature of systolic
compression among many DCC devices, augmented pulsatility is likely a feature of
external compression and may have implications in acute support compared to
continuous flow blood pump.
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Aim 2: Is myocardial stretch and LV morphology altered during DMVA support of
the failing heart?

This study has reaffirmed DMVA’s ability to augment longitudinal strain and strain rates
relative to HF and baseline. Strain is generally regarded as a proxy measure for
myocardial stretch while strain rate is a proxy measure for compressive force. However,
most studies involving longitudinal strain analysis has focused on strain/strain rate peak
magnitudes. The composite waveform analysis in this study predictably revealed
substantially augmented strain and strain rates during DMVA compared to HF
throughout the entire cycle. More importantly, DMVA strain and systolic strain rate
composite waveforms at the very least matched baseline magnitudes. However, DMVA’s
diastolic strain rate composite waveforms displayed higher early diastolic relaxation
relative to baseline. The unique active diastolic assist during DMVA likely accounts for
this augmentation and would not be present in DCC relying solely on passive diastolic
relaxation. DMVA’s suction effect has always been thought a key feature of the device
and shows promise for addressing the diastolic dysfunction characteristic of many
pathologies.

Aim 3: Does DMVA support of the acutely failing heart improve intraventricular
mechanical synchrony?

Comparisons between states using various DI metrics showed baseline < HF < DMVA
ordering which suggested DMVA may transiently increase dyssynchrony. However, this
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relationship was only observed during support of hearts with higher underlying function
(+66% baseline aortic flows). DMVA-induced timing differences responsible for higher
DI values were localized to the apical and apical mid-wall LV regions. Whether these
changes in cardiac timing were actually detrimental (particularly during long-term
support in chronic pathologies) was beyond the scope of this study.

Aim 4: Does DMVA support interact with the acutely failing heart to alter
hemodynamic coordination?

The wide range of CI values calculated for HF support suggested coordination between
the device and heart varied greatly throughout the study. By definition, VF had near
perfect coordination due to a lack of meaningful native cardiac function. Greater
underlying function during support inhibited coordination. Better coordination was
strongly associated with higher maximum device pressures and +dP/dt. These metrics are
the primary indicators of the extent of device-imposed stretch, suggesting greater stretch
and compression increased coordination between the device and heart. Weaker
coordination was associated with increased frequency of exception cycles (skipped and
unsynchronized cycles), suggesting weaker coordination could more readily degrade into
cycles with poor hemodynamics or loss of ventricular capture. Unsynchronized cycles
were characterized by an early intrinsic hemodynamic peak well before DMVA’s peak
mechanical stimulus.
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General Discussion

Lack of blood contact is the defining characteristic of DCC in relation to existing blood
pump technology. Blood contact comes with a host of potential complications including
higher risk of infection, disruption of the blood’s molecular milieu due to higher shear
forces, exposure to at least semi-incompatible surfaces, and invasive cannulation
procedures during installation. Direct actuation of the native heart structure may also
provide some benefit to myocardial recovery. Blood pumps, typically positioned parallel
to the native heart structure, unload the heart by supplementing pump function. The
resulting attenuation of pathologic hemodynamics due to unloading allows for beneficial
remodeling and recovery. However, simple unloading enables what may best be
described as atrophic remodeling given the workload of the heart is substantially reduced.
While beneficial when correcting pathological hypertrophy, excessive unloading may
promote pathologic cardiac atrophy. The DCC mechanism modulates the myocardium
during support in a manner distinct from simple unloading. Supplementing heart function
while actuating heart tissue directly enables more physiologic cellular signaling and
conditioning.

The most limiting factor of DCC is size, primarily due to the fluid-medium drive system,
constraining implantability. The end goal of most experimental DCC systems is adapting
existing designs to be fully implantable. Other challenges to DCC development,
compared to blood pump technology, are the higher wear rates needed to cyclically
actuate the heart surface and flow limitations for pumping the native heart structure.
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While DCC comes with its own set of challenges, the substantial benefits of such devices
and recent improvements in design should generate future interest in the technology.

This study demonstrated DMVA can provide physiologic support under optimal
conditions. While the device pressure waveform is crucial to device function, more subtle
factors such as an open chest and respiratory artifact, positioning of the device over the
heart, and the underlying state of the heart are important. Inherent contractility and
imposed strain from DCC theoretically have an additive relationship that enhances
cardiac support. However, this effect was limited by interference between these two
forces in more robust and healthy hearts. DCC in general appears to have a derogatory
effect on pump function when cardiac outputs were at least 70-80% baseline before
support. For this reason, DMVA hemodynamics were generally lower than baseline
physiology even under more optimal conditions.

While hemodynamics somewhat lagged baseline physiology, DMVA substantially
augmented pulsatility relative to HF and baseline. This feature is critically important for
resuscitation where success is largely predicated on the timely return of physiologic flow.
Prior investigations provided compelling evidence DMVA improved cerebral
resuscitation outcomes and neurological recovery compared to CPB in animal models. It
is thought these findings were largely the result of pulsatile flow generated by DMVA.
However, pulsatile flow during DMVA support had not been characterized in a
meaningful manner. While the mechanism for this augmentation is not well understood
(increases cannot be ascribed simply to lower continuous flow components of the
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metrics), improved pulsatility and perfusion are important considerations for DMVA’s
role as a resuscitation device.

Longitudinal strain and strain rate data suggested DMVA was able to stretch the heart
wall in a roughly similar fashion to the baseline heart, albeit in a hyperdynamic manner.
This does not necessarily mean the LV shape during compression is similar, only that the
wall is stretched in a similar fashion (with all its implications for stretch-dependent
cellular signaling). DMVA theoretically produces an hourglass shape (inversion) when
inflated, but calculations of heart profiles were beyond the scope of this study. Given the
average maximum compression of the device is experienced at the border between the
apex and mid-wall, an apical to basal compression profile may be favored over the
inverted profile (which requires a mid-wall compression maximum).

Diastolic assist is a unique feature of DMVA. Other DCC devices maintain an active
compression phase and rely on native diastolic function for filling. Given diastolic
dysfunction is often an early feature of cardiac remodeling during HF, ignoring diastolic
support with external compression could compound already existing pathologies. This
study provided evidence of a significant assist effect during early diastole. The extent of
this diastolic assist effect remains unclear given the interface between DMVA and the
heart was not examined during this study.

Externally imposed actuation created earlier compression in the apical and mid-walls. It
seemed reasonable to assume external compression might induce some timing
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irregularities considering the mechanism in relation to myofibril contraction. However,
higher calculated dyssynchrony during DMVA was not obviously detrimental to support
quality and readily reverted to lower values upon device removal. While higher
dyssynchrony did not have much impact during the acute timeframe of experiments in
this study, the long-term implications of these changes are unknown. There is a scarcity
of information about the long-term effects of DCC given the relative lack of extended
support testing (>1 month). The recent resurgence of interest in DCC may spur the
discovery of more information in the next decade.

DMVA support without electrical pacing during HF created highly variable levels of
coordination between the device and heart. Higher device pressure and +dP/dt were
shown to strongly increase coordination and suggested some manner of mechanical
coordination. The absence of any form of electrical pacing suggested the coordination
effect observed with higher device pressures originated from device-imposed stretch.
Such an effect has been verified with cyclic stretch imposed on cardiac tissue cultures
and indenters on isolated heart preparations. However, the principle had not been
demonstrated in the intact heart, particularly with a clinically relevant DCC device.
Additionally, unsynchronized cycles and poor hemodynamic response (skipped captures)
accompanied decreasing coordination. This suggested mismatches between the device
and hemodynamic response are a risk factor for loss of capture and weaker hemodynamic
outcomes. the device and heart.
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Novelty

TEE images are typically used to calculate strain and strain rate for assessing cardiac
assist devices. In this study ICE was utilized to optimize image quality. Viable TEE
views were restricted to upper esophageal views by the air interface of the pneumatic
DCC wrapped around the ventricular epicardium. ICE probe positioning also allowed for
closer proximity to the LV. Images were acquired with planes roughly corresponding to
more established long-axis, 4-chamber, and short-axis TEE slices. However, only the 4chambered view was analyzed in depth because it was the most readily capturable and
well-represented in the data pool.

Most analyses involving strain and strain rate utilize peak values as a surrogate for
cardiac stretch and compression, respectively. While this representation is relatively
forgiving in terms of data quality, relying on peak data ignores most of the waveform.
Composite waveforms were developed for more detailed comparisons between
experimental states. A visual representation with statistical testing at periodic time points,
as opposed to creating a series of new descriptive variables (e.g. time between opposing
peaks), was chosen to ease comprehension. Composite waveforms were standardized to a
uniform cycle length and aligned by both systolic and diastolic peaks. The aligned peak
revealed quantitative information about magnitudes while the opposite peak revealed
information about timing and relative magnitudes.
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The coordination analysis used the theoretical approach from tissue and isolated heart
studies (matching a mechanical signal and cardiac response) and applied it to intact
hearts. Mechanical stimuli created with indenters or cell stretching rigs are replaced with
stretch imposed by DMVA. DCC, using devices made for clinical support, is a real-world
source of imposed cardiac stretch. Given the lack of electrical pacing during DMVA, the
degree of coordination can be considered a measure of a maintaining ventricular capture.
Unsynchronized cycles were only observed in data with high CI, suggesting weaker
coordination came with a tendency to lose ventricular capture.

DCC devices in general are not particularly well understood due to comparatively few
devices being developed relative to other cardiac assist modalities. Most DCC device
testing has focused on the efficacy of the device for supporting pathologic hearts. Given
this, many of the concepts which would best promote DCC use remain untested e.g.
external actuation of the heart tissue prevents atrophic remodeling, actuation of the native
heart structure is able to replicate physiologic cardiac motions. Given all the questions
surrounding DCC use, this study can best be understood as an initial foray into defining
DCC mechanics for future research.

Future Direction

Diastolic suction is a unique feature of DMVA relative to other DCC devices. An apical
vacuum establishes a seal between the epicardial surface and device membrane. The seal
facilitates diastolic assist as the retracting device membrane pulls the heart toward the
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outer shell. This study demonstrated diastolic assist enhanced early diastolic retraction.
The equivalence of baseline and DMVA LV end-diastolic volumes suggested this
diastolic effect only occurred until native diastolic LV volumes were achieved. While
there appears to be measurable diastolic assist, understanding of this feature remains
limited given the focus on systolic function in assist devices. Investigation of seal
strength throughout the entire diastolic phase, principally using force sensors and visual
tracking during support in a mock circulatory system, could verify the extent of diastolic
assist.

Despite the relative biofidelity of DMVA to baseline function (likely due to the device
actuating the native heart structure), how the device augments pulsatility to the extent
seen in this study remains unknown. Animal experiments have numerous confounding
factors making definitive conclusions about mechanisms difficult to develop. A mock
circulatory system with anatomical and akinetic silicone ventricles can be used to assess
how pulsatility is generated during DMVA. Pulsatility is likely to be affected by factors
such as device placement, pneumatic pressure magnitudes, and vascular interactions. All
of these factors can be readily tested in a reproducible and exact manner using the
proposed mock system.

The effect of coordination can also be examined with the development of a beating
silicone ventricle. A beating heart model would entail using another DCC arrangement
imbedded in the silicone to represent native contractility. Any CI pattern can be
reproduced using this setup to quantify interactions between intrinsic function and
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external compression of the silicone ventricles. The lack of confounding variables will
likely underscore the importance of good coordination as it pertains to mechanical
pacing.

Overall, DMVA is well-suited to a resuscitative role for cardiac arrest and severe HF.
This study demonstrated DMVA is capable of restoring physiologic pulsatility,
hemodynamics, and LV strain patterns in an acute animal model of cardiac arrest.
Renewed interest in DCC due to the shortcomings of blood-contacting VAD’s has the
potential to revolutionize treatment of cardiac pathologies. However, additional questions
about device-ventricular coupling in the intact heart and design modifications to allow for
greater drive implantability will need to be addressed before many long-term roles for
DCC can be realized.
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